Index

ACCESS DENIAL
To essential facility, as anticompetitive conduct under Section 2 of Sherman Act, **§ 6:8**

ACCOUNTABLE CARE ORGANIZATION SUMMIT
A Common Goal: The U.S. Federal Trade Commission's Healthcare Enforcement Program and its Implications for ACOs, text of remarks by Julie Brill, Commissioner, FTC, before the Sixth Annual Summit Preconference (June 17, 2015), **App. E110**
Antitrust Enforcement in Health Care: Proscription, Not Prescription, text of remarks by Deborah L. Feinstein, Director, Bureau of Competition, FTC, before the Fifth National Summit (June 19, 2014), **App. E98**

ACMG, INC.
Advisory opinion, **App. D43**

ACQUISITIONS
Mergers (this index)

ADMINISTRATIVE COMPLAINT
Caremark Rx, LLC, et al., **App. G25**
Edwards Lifesciences Corp. and JenaValve Technology, Inc, in matter of, **App. G38**
Lawsuits, **App. G25**
Matter of GTCR BC Holdings, LLC and Surmodics, Inc
FTC Matter/File Number 241 0095, Docket Number 9440, **App. G32**
Novant Health, Inc. and Community Health Systems, Inc., in matter of, **App. G18**

ADVANCED PRACTICE NURSING
Florida House of Representatives, FTC letter concerning regulation of advanced registered nurse practitioners, **App. D135**
FTC advocacy letter to Veterans Administration, restrictions (July 25, 2016), **App. D183**
FTC collaborative practice agreements between advanced practice registered nurses and physicians, **App. D147**
FTC Executive Summary, ''Policy Perspectives: Competition and Regulation of Advanced Practice Nurses'' (Mar. 2014), **App. E95**
Kentucky State Senate, FTC letter concerning bill relating to advanced practice registered nurses scope of practice, **App. D145**
Letter from Office of Policy Planning Acting Director Clarke Edwards to Senator Juan Barnett Concerning Mississippi H.B. 1057 to Address the Practice of Advanced Practice Registered Nurses (January 25, 2026), **App. F15**
Missouri House of Representatives, FTC Staff advocacy letter regarding advanced practice registered nurses, **App. D164**
South Carolina House of Representatives, FTC advocacy letter concerning supervision of advanced practice nurses (Nov. 2, 2015), **App. D173**
Texas State Senate, FTC letter concerning regulation of advanced registered nurse practitioners, **App. D137**
West Virginia Senate, FTC Staff Advocacy letter concerning placing regulation of advanced

ADVANCED PRACTICE NURSING —Cont'd

ADVANCED PRACTICE NURSING —Cont'd
practice registered nurse under State Board of Medicine and Osteopathy (Feb. 10, 2016), **App. D176**

ADVERTISING
Clinic advertising, FTC staff letter to Massachusetts Department of Public Health concerning (Sept. 27, 2007), **App. D117**
Limitations on, ethical restraints, **§ 24:6**

ADVISORY OPINIONS
ACMG, Inc., **App. D43**
Alaska House of Representatives, physician joint negotiation statute (Jan. 18, 2002), **App. D90**
Alliance of Independent Medical Services, LLC (Dec. 22, 1997), **App. D78**
Alpena Public Schools (June 16, 2006), **App. D111**
American Dental Association (Aug. 26, 1985), **App. D15**
American Dental Association (Feb. 15, 1990), **App. D28**
American Intra-Ocular Implant Society, **App. D17**
American Medical Association (March 26, 1996), **App. D60**
American Medical Association and Chicago Medical Society, **App. D41**
American Podiatry Association (Aug. 18, 1983), **App. D4**
American Podiatry Association (March 13, 1984), **App. D7**
Arkansas Children's Hospital (March 13, 2003), **App. D98**
Associates in Neurology (Aug. 13, 1998), **App. D81**
Association of Quality Health Care, **App. D22**
Attorney General of Montana regarding any-willing-provider laws, **App. D36**
Attorney General of North Dakota regarding cooperative arrangements among hospitals, **App. D37**

ADVISORY OPINIONS—Cont'd
Bay Area Preferred Physicians, **App. D102**
BJC Health System (Nov. 9, 1999), **App. D85**
Business Health Companies, Inc.
(Oct. 19, 1996), **App. D64**
(Oct. 18, 1996), **App. D70**
California All Health, **App. D50**
California Managed Imaging Medical Group, Inc., **App. D39**
California Senate regarding any-willing-provider laws, **App. D33**
Central Texas Medical Group (Sept. 28, 1995), **App. D56**
Columbine Family Health Center (Nov. 8, 1995), **App. D57**
Columbus Hospital (June 28, 1996), **App. D63**
Community Hospital, Inc. (Dec. 22, 1997), **App. D77**
Competition law and policy, prospective guidance FTC advisory opinions (June 26, 2002), **App. E21**
Connecticut Hospital Association (Dec. 20, 2001), **App. D89**
District of Columbia Corporation Counsel, **App. D86**
Dunlap Memorial Hospital, FTC staff advisory opinion to (Jan. 6, 2004), **App. D103**
Eastern Ohio Physicians Organization, Inc. (Sept. 28, 1995), **App. D55**
Elmore Community Hospital and Community Hospital, **App. D51**
Equitable Life Assurance Society of the United States, **App. D21**
Erlanger Medical Center and Memorial Hospital, **App. D49**
First Look, LLC (June 19, 1997), **App. D75**
Foundation for the Accreditation of Hematopoietic Cell Therapy (Apr. 17, 1997), **App. D72**
FTC
generally, **§ 10:7, App. B5, App. D**

ADVISORY OPINIONS—Cont'd
FTC—Cont'd
see also other entries throughout this topic
Generic Pharmaceutical Association (Aug. 8, 2012), **App. D149**
Gilbert M. Frimet, **App. D8**
Greater Rochester Independent Practice Association (Sept. 17, 2007), **App. D116**
Harvard Vanguard Medical Associates, Inc. (Dec. 18, 2001), **App. D88**
Health Care Management Associates, **App. D3**
Hematology/Oncology Care Specialists of Western Pennsylvania, P.C. (Sept. 21, 1995), **App. D54**
Henry County Memorial Hospital (Apr. 10, 1997), **App. D74**
Intracorp, **App. D26**
Kaiser Foundation Health Plan (Feb. 13, 2008), **App. D119**
Kitsap Physicians Service (March 26, 1984), **App. D9**
Kitsap Physicians Service (May 22, 1984), **App. D11**
Louisiana Health Care Association, **App. D2**
Lynch, Patrick C. (Rhode Island Attorney General), FTC staff letter to (Apr. 8, 2004), **App. D104**
Maryland Medical Eye Associates, **App. D25**
Massachusetts Department of Public Health, FTC staff letter concerning clinic advertising (Sept. 27, 2007), **App. D117**
Mayo Medical Laboratories (July 17, 1996), **App. D61**
Medical Group Management Association, staff advisory opinion to, **App. D101**
Medical Society of the County of Erie, **App. D6**
MedSouth, Inc. (Feb. 19, 2002), **App. D92**
MedSouth, Inc., FTC staff follow-up letter (June 18, 2007) to 2002 advisory opinion, **App. D115**
Mesa County Physician Independent Practice Association (Nov. 6, 1997), **App. D76A**
Michael A. Duncheon, **App. D20**
Michael D. McNeely, Assistant Director, Bureau of Competition, to Clifton E. Johnson, **App. D42**
Missouri Board of Chiropractic Examiners regarding free or discounted services, **App. D35**
Mobile Health Resources, LLC (Jan. 23, 1997), **App. D67**
Montana Deaconess Medical Center (June 28, 1996), **App. D63**
Montana House of Representatives involving denturists, **App. D34**
National Capital Society of Plastic and Reconstructive Surgeons (Apr. 23, 1991), **App. D30**
New Hampshire Senate regarding any-willing-provider laws, **App. D32**
New Jersey Pharmacists Association (Aug. 12, 1997), **App. D76**
North Carolina Chiropractic Association, **App. D5**
Northeast Pharmacy Service Corporation (July 27, 2000), **App. D87**
North Mississippi Health Services
(Oct. 3, 1996), **App. D69**
(Jan. 7, 1998), **App. D79**
(Aug. 16, 2005), **App. D109**
North Ottawa Community Hospital (Oct. 22, 1996), **App. D71**
North Texas Chapter, American College of Surgeons, **App. D18**
Northwestern Nevada Orthopaedic Surgery Alliance, **App. D52**
Oakland Physician Network, **App. D48**
Ohio Ambulance Network, Inc. (Jan. 23, 1997), **App. D66**
Orange Pharmacy Equitable Network (May 19, 1999), **App. D84**
Otolaryngology Specialty Providers of Georgia, **App. D53**

ADVISORY OPINIONS—Cont'd
Pacific International Health, **App. D23**
Palmetto Dental Alliance, **App. D46**
Pan American Management Associates, **App. D27**
Passaic County Medical Society, **App. D19**
Peer Review Organizations of Ohio Foundation, **App. D10**
Phoenix Medical Network, Inc. (May 19, 1998), **App. D80**
Physician IPA that sponsors a PPO, **App. D31**
Presentation Health System, **App. D40**
PriMed Physicians (Feb. 6, 2003), **App. D96**
Private Healthcare Systems, **App. D16**
Rhode Island Attorney General (Patrick C. Lynch), FTC staff letter to (Apr. 8, 2004), **App. D104**
Rocky Mountain Cardiovascular Affiliates, **App. D47**
Senator Orrin G. Hatch regarding hospital mergers, **App. D38**
Southeast Managed Care, Inc., **App. D44**
Southern Arizona Therapy Network, Inc. (Dec. 7, 1995), **App. D58**
Southwest Florida Oral Surgery Associates (Dec. 2, 1996), **App. D65**
Staff letter to State of Washington House of Representatives concerning physician joint negotiation statute (Feb. 8, 2002), **App. D91**
Statement Regarding Physician Agreements to Control Medical Prepayment Plans, **App. D1**
Stevens Hospital, staff advisory opinion to (Apr. 18, 2005), **App. D107**
St. John's Health System (Sept. 13, 2006), **App. D112**
Suburban Health Organization, Inc., FTC staff advisory opinion to (March 28, 2006), **App. D110**

ADVISORY OPINIONS—Cont'd
Suffolk County Dental Society, **App. D45**
Tarrant County Medical Society (July 11, 1984), **App. D13**
Tarrant County Medical Society (May 25, 1984), **App. D12**
Texas House of Representatives Concerning Joint Negotiations by Physicians (May 13, 1999), **App. D83**
TriState Health Partners, FTC letter not to recommend challenge of proposed "clinical integration" of members' provision of health care services (Apr. 13, 2009), **App. D124**
URONET of Louisiana, LLC (Jan. 23, 1996), **App. D59**
Utah Society of Oral and Maxillofacial Surgeons, **App. D14**
Valley Baptist Medical Center (March 13, 2003), **App. D97**
Valley Baptist Medical Center (Sept. 19, 1996), **App. D68**
Views on HMO Exclusive Contracts, **App. D24**
Viquest and Pitt Country Memorial Hospital (Mar. 8, 2002), **App. D94**
Washington House of Representatives, physician joint negotiation statute (Feb. 8, 2002), **App. D91**
Wesley Health Center, Inc. (Apr. 29, 1999), **App. D82**
Wichita, Kansas, Chamber of Commerce, **App. D29**
William W. Backus Hospital (June 11, 1996), **App. D62**
Yellowstone Physicians, LLC (May 14, 1997), **App. D73**

AFFORDABLE CARE ACT
Integration, Consolidation, Competition in the Wake of the Affordable Care Act, text of remarks of Bill Baer, Assistant Attorney General, before the New Health Care Industry Conference (Nov. 15, 2015), **App. E114**
Mergers, analyzing hospital, **§ 15:22**

AFFORDABLE CARE ACT —Cont'd
Respecting proposed regulations implementing, statement by FTC Commissioner, **App. E63**

AGREEMENTS
Amgen Inc. and Horizon Therapeutics plc, FTC File No. DO9414, **App. G16**
Bid-rigging agreements, under Section 1, Sherman Act, **§ 4:5**
Business Review Letter to CEO Roundtable on clinical trial agreements for cancer treatments (Sept. 28, 2008), **App. C99**
Employee non-compete agreements, ethical restraints, **§ 18:4**
Exclusionary Dealing Agreements (Hospital/Physician) (this index)
Horizontal Agreements (this index)
Market-Allocation Agreements (this index)
Participation agreements between providers and payers, health plan market power, **§ 21:3**
Price-Fixing Agreements (this index)
Reciprocal dealing agreements as vertical agreements under Section 1 of Sherman Act, **§ 5:8**
Sherman Act Section 1 violations
generally, **§ 3:2 to 3:6**
see also specific types of agreements
capacity to conspire, **§ 3:5**
conspiracy in fact, **§ 3:6**
Vertical Agreements (this index)

"A HEALTH CARE CHECK ON COPAS; ASSESSING THE IMPACT OF CERTIFICATES OF PUBLIC ADVANTAGE IN HEALTH CARE MARKETS" (JUNE 18, 2019)
Joseph J. Simons, remarks, FTC workshop, **App. E127**

ALASKA HOUSE OF REPRESENTATIVES
Advisory opinions, physician joint negotiation statute (Jan. 18, 2002), **App. D90**
Certificate-of-need laws and Alaska, joint statement of FTC and Antitrust Division (Apr. 7, 2017), **App. D189**
Federal Trade Commission prepared statement concerning certificate of need (Feb. 15, 2008), **App. E45**
Telehealth services, FTC Advocacy letter to State Legislature concerning (Mar. 25, 2016), **App. D179**

ALASKA SENATE
Certificate-of-need laws and Bill 62. FTC Statement (Feb. 6, 2018), **App. D192**
Committee on Labor and Commerce, Certificate-of-Need Laws and SB 62, statement of FTC (Feb. 6, 2018), **App. E119**

ALLERGY & ASTHMA CONSULTANTS, INC.
Business review letter (March 19, 1996), **App. C66**

ALLIANCE OF INDEPENDENT MEDICAL SERVICES, LLC
Advisory opinions (Dec. 22, 1997), **App. D78**

ALLIED COLON AND RECTAL SPECIALISTS
Business review letter (July 1, 1996), **App. C69**

ALLIED HEALTH PRACTITIONERS
In credentialing process, **§ 13:19**

ALL-PRODUCTS PROVISIONS
Health plan market power, payer monopoly power and all-products provisions, **§ 21:7**

ALPENA PUBLIC SCHOOLS
FTC staff advisory opinion to (June 16, 2006), **App. D111**

AMBULATORY SURGERY CENTERS (ASCS)
Physician-owned facilities, **§ 18:2 et seq.**

AMERICAN ANTITRUST INSTITUTE
Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care, text of remarks of Martin Gaynor, Director, Bureau of Economics, FTC, before the 2014 Annual Conference, **App. E100**

AMERICAN ASSOCIATION OF OPHTHALMOLOGY
Business review letter, **App. C8**

AMERICAN BAR ASSOCIATION
Antitrust Analysis of Reverse Payments After Actavis: Three Questions and Proposed Answers, text of remarks of Joshua D. Wright, Commissioner, FTC, before the ABA Master Course VII (Oct. 10, 2014), **App. E101**
Enforcement Strategies in the Health Care Industry, prepared remarks of J. Thomas Rosch before ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E48**
Observations on and From the Antitrust Division's buyer-side cases: How can 'lower' prices violate the antitrust laws, remarks of Mark Botti at Antitrust Law Spring Meeting (Apr. 19, 2007), **App. E40**
Origin of the Species: The 100 Year Evolution of the Clayton Act, text of remarks of William J. Baer, Assistant Attorney General, Antitrust Division, before the ABA Clayton Act 100th Anniversary Symposium (Dec. 4, 2014), **App. E103**
Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission, Joshua D. Wright before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E88**
What's Past is Prologue: FTC's Competition and Consumer Protection Priorities, text of remarks by Julie Brill, Commissioner, FTC, before the ABA Fall Forum (Nov. 6, 2014), **App. E102**

AMERICAN DENTAL ASSOCIATION
Advisory opinions
August 26, 1985, **App. D15**
February 15, 1990, **App. D28**

AMERICAN HEART ASSOCIATION
Business review letter, **App. C27**

AMERICAN HEART ASSOCIATION PHARMACEUTICAL ROUNDTABLE
Business review letter (Mar. 20, 1998), **App. C85**

AMERICAN HOSPITAL ASSOCIATION
Business review letter, **App. C5**
Clinical Integration: The Changing Climate and What It Means for Care Coordination, remarks of Pamela Jones Harbour, Commissioner, FTC at annual membership meeting (Apr. 27, 2009), **App. E51**

AMERICAN INTRA-OCULAR IMPLANT SOCIETY
Advisory opinion, **App. D17**

AMERICAN MEDICAL ASSOCIATION
Advisory opinions (March 26, 1996), **App. D60**
Antitrust Division Letter (Dec. 2, 1986), **App. C20**

AMERICAN MEDICAL ASSOCIATION—Cont'd
Business Review Letter (March 9, 1979), **App. C7**
Business review letter and advisory opinion
February 14, 1994, **App. D41**

AMERICAN PODIATRY ASSOCIATION
Advisory opinions
August 18, 1983, **App. D4**
March 13, 1984, **App. D7**

AMERICAN RED CROSS
Business review letter, **App. C21**

AMGEN INC. AND HORIZON THERAPEUTICS PLC, FTC FILE NO. DO9414
Consent order agreement, **App. G16**

AMICUS BRIEF
FTC, Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals, **App. D202**

ANCILLARY PRICE-FIXING AGREEMENTS
Provider-controlled contracting networks, clinical integration, **§ 20:8**

ANDREW N. FERGUSON & MELISSA HOLYOAK STATEMENT
Gateway Pet Memorial Services, **App. F9**

ANNUAL ANTITRUST SEMINAR
"The Rhetoric of Gun Jumping," remarks before Association of Corporate Counsel Annual Antitrust Seminar of Greater New York Chapter (Nov. 10, 2005), **App. E34**

ANNUAL REPORT
FTC and Department of Justices 44th Hart-Scott-Rodino, **App. D204**

ANTHEM, INC.
Acquisition of WellPoint Health Networks, Inc., Antitrust Division statement on closing of investigation of (March 9, 2004), **App. E30**

ANTHEM, INC.—Cont'd

ANTICOMPETITIVE CONDUCT (MONOPOLIZATION)
Generally, **§ 6:4**
Denial of access to essential facility, **§ 6:8**
Leveraging, **§ 6:9**
Mergers, **§ 6:11**
Monopoly pricing, **§ 6:5**
Other predatory or unreasonably exclusionary conduct, **§ 6:12**
Predatory pricing, **§ 6:6**
Refusals to deal, **§ 6:7**
Vertical integration, **§ 6:10**

ANTICOMPETITIVE EFFECT ELEMENT (SHERMAN ACT SECTION 1 VIOLATIONS)
Hybrid analyses, **§ 3:13**
Per se rule, **§ 3:12**
Rule of reason, **§ 3:11**
Unreasonably, generally, **§ 3:10**

ANTICOMPETITIVE PURPOSE OR INTENT ELEMENT
Civil antitrust cases, **§ 3:8**
Criminal antitrust cases, **§ 3:9**
Intent in criminal antitrust cases, **§ 3:9**
Of Sherman Act Section 1 violations, **§ 3:7**
Purpose and intent in civil antitrust cases, **§ 3:8**

ANTITRUST, JUDICIARY SUBCOMMITTEE
Competition Policy and Consumer Rights Oversight of the Enforcement of the Antitrust Laws, United States Senate Committee on the Judiciary Subcommittee on Antitrust, **App. E146**

"ANTITRUST ANALYSIS OF HOSPITAL NETWORKS AND SHARED SERVICES ARRANGEMENTS"
(Speech), **App. E12**

"ANTITRUST AND HEALTH CARE PROVIDERS: POLICIES TO PROMOTE COMPETITION AND PROTECT PATIENTS"
Rebecca Kelly Slaughter, prepared remarks, **App. E126**

ANTITRUST CIVIL PROCESS ACT
Generally, **App. A9**

ANTITRUST DEFENSES
See also Defenses (this index)
To defense actions in nonantitrust cases, **§ 11:12**

ANTITRUST DIVISION
Price Fixing, Bid Rigging, and Market Allocation Schemes
what they are and what to look for, antitrust primer
Department of Justice, **App. G47**

ANTITRUST DIVISION, DEPARTMENT OF JUSTICE
Justice Department (United States Department of Justice; Antitrust Division) (this index)

ANTITRUST GUIDELINES
Federal trade commission (ftc)
DOJ and FTC Antitrust Guidelines for Business Activities Affecting Workers
(January 2025), **App. G34**

ANTITRUST GUIDELINES FOR COLLABORATIONS AMONG COMPETITORS
Generally, **App. G1**

ANTITRUST/HEALTH CARE GUIDELINES
Generally, **App. F**
ABA/AHLA Antitrust in Healthcare Conference, Christine A. Varney prepared remarks, **App. E57**
''An Ounce of Antitrust Prevention is Worth a Pound of Consumer Welfare: The Importance of Competition Advocacy and Premerger Notification,'' before

ANTITRUST/HEALTH CARE GUIDELINES—Cont'd
Eleventh Annual Competition Day, Santiago, Chile (Nov. 5, 2013), **App. E91**
''Antitrust and Health Care Providers: Policies to Promote Competition and Protect Patients,'' Rebecca Kelly Slaughter, prepared remarks, **App. E126**
Antitrust Division Evaluation of Corporate Compliance Programs in Criminal Antitrust Investigations (November 2024), **App. G28**
Antitrust in Healthcare Conference: A Prescription for Competition, Bernard A. Nigro, Jr., prepared remarks, **App. E125**
FTC topic and yearly indices of advisory opinions, commission and staff (December 2025), **App. G7**
''Patent Settlements, Patent Reform, and Mergers: Recent Developments in Pharmaceutical Antitrust,'' **App. E65**
Telehealth services, advocacy letter from Antitrust Division (Nov. 29, 2016), **App. C103**
''The FTC's Role in Shaping Antitrust Doctrine: Recent Successes and Future Targets,'' Joshua D. Wright before the 2013 Georgetown Global Antitrust Symposium Dinner, Washington, D.C. (Sept. 24, 2013), **App. E89**
US GAO Report, stakeholders perspectives, adequacy of guidance, **App. B15**

"ANTITRUST IN HEALTHCARE: A KEYNOTE ADDRESS"
(Speech), **App. E27**
FTC chairwoman, Health Law Conference (May 12, 2016), **App. E118**

ANTITRUST IN HEALTHCARE CONFERENCE: A PRESCRIPTION FOR COMPETITION
Remarks, text of, prepared for, **App. E125**

ANTITRUST IN HEALTH CARE SEMINAR
"Clinical Integration in Antitrust: Prospects for the Future," remarks before AHLA and ABA Antitrust and Health Law Section 2007 Antitrust in Health Care Seminar, prepared remarks of J. Thomas Rosch, Commissioner, FTC (Sept. 17, 2007), **App. E42**

ANTITRUST LAW 2007 FALL FORUM
Prepared slides of Jeffrey Schmidt, Director, Bureau of Competition, before ABA Section concerning "Critical Loss Analysis: A Merger Lawyer's View" (Nov. 16, 2007), **App. E44**

ANTITRUST LAWS
Generally, **§ 1:1**
See also more specific entries throughout this index
Conclusion, **§ 1:9**
Federal government guidelines, **§ 1:8**
Goals of, **§ 1:4**
Government enforcement statements, **§ 1:7**
Health care and, **§ 1:5**
History and overview of, **§ 1:3**
History of enforcement of, in health care sector, **§ 1:6**
Legislative changes, **§ 1:7**
Managed care, effect of, **§ 1:7**
Provider-controlled contracting networks, price-fixing agreements, **§ 20:11**
Purpose and definition of, **§ 1:2**
Relevant federal, in mergers, **§ 15:3**
Resources, **§ 1:10**

ANTITRUST SAFETY ZONE
Provider-controlled contracting networks, **§ 20:5, § 20:6**

ANY-WILLING-PROVIDER LAWS (FTC LETTERS)
To the Attorney General of North Dakota regarding, **App. D36**
To the California Senate regarding, **App. D33**
To the New Hampshire Senate regarding, **App. D32**

APRNS
Senator Brad Hutto FTC Clarke Edwards Letter, **App. D209**

ASSOCIATES IN NEUROLOGY
Advisory opinions (Aug. 13, 1998), **App. D81**

ASSOCIATION OF CORPORATE COUNSEL
"The Rhetoric of Gun Jumping," remarks before Association (Nov. 10, 2005), **App. E34**

ASSOCIATION OF QUALITY HEALTH CARE
Advisory opinion, **App. D22**

ATTEMPTED MONOPOLIZATION
Diversification and, under Section 2, Sherman Act
generally, **§ 17:8**
essential facilities doctrine and, **§ 17:10**
leveraging and, **§ 17:11**
predatory refusals to deal, **§ 17:9**
Under Section 2, Sherman Act
generally, **§ 6:13**
dangerous probability of success, **§ 6:15**
specific intent and predatory conduct, **§ 6:14**

AUTHORITY
FTC enforcement, **§ 10:7**

BAER, WILLIAM J.
"Origin of the Species: The 100 Year Evolution of the Clayton Act," text of remarks of William J.

BAER, WILLIAM J.—Cont'd
Baer, Assistant Attorney General, Antitrust Division, before the ABA Clayton Act 100th Anniversary Symposium (Dec. 4, 2014), **App. E103**

BARRIERS TO GENERIC ENTRY
Special Committee on Aging, U.S. Senate, Prepared Statement of FTC Before (July 20, 2006), **App. E37**

BATES WHITE ANNUAL ANTITRUST CONFERENCE
''Litigating Merger Challenges: Lessons Learned,'' prepared remarks by J. Thomas Rosch at Fifth Annual Antitrust Conference (June 2, 2008), **App. E47**

BAXTER HEALTHCARE CORPORATION
Business review letter, **App. C26**

BAY AREA BUSINESS GROUP ON HEALTH
Business review letter, **App. C37**

BAY AREA PREFERRED PHYSICIANS
Advisory opinion, **App. D102**

BEDOYA, ALVARO M.
Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E147**

BEIJING, CHINA
Joshua D. Wright, ''Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission,'' before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E88**

BIDDING
Agreements not to engage in competitive, ethical restraints on, **§ 24:4**

BID-RIGGING AGREEMENTS
Horizontal, under Section 1, Sherman Act, **§ 4:5**

"BIGGER THAN BIG TECH, THE NEED TO REFORM OUR HEALTH CARE SYSTEM USING CHOICE AND COMPETITION," CHRISTINE S. WILSON (SEPTEMBER 9, 2019)
Generally, **App. E128**

BIOSIMILARS
FDA/FTC workshop
competitive marketplace for biosimilars, **App. D203**
opening remarks of Chairman Joseph Simons, **App. E130**

BIRMINGHAM COOPERATIVE CLINICAL BENCHMARKING DEMONSTRATION PROJECT
Business review letter, **App. C42**

BISHOP, MICHAEL D.
Antitrust Division letter to Michigan Senate Majority Leader Bishop concerning proposed standards of Michigan Certificate of Need Commission (June 6, 2008), **App. C98**

BJC HEALTH SYSTEM
Advisory opinions (Nov. 9, 1999), **App. D85**

BLUMENTHAL, WILLIAM
''The Rhetoric of Gun Jumping,'' remarks before Association of Corporate Counsel Annual Antitrust Seminar of Greater New York Chapter (Nov. 10, 2005), **App. E34**

BONE & JOINT CENTER OF MOBILE
Business review letter (Apr. 16, 1997), **App. C79**

BOYCOTTS
Physician-owned facilities, **§ 18:3**

BOYCOTTS—Cont'd
Practitioner credentialing, analysis under Section 1 of Sherman Act, **§ 13:10 to 13:17**

BRIBERY
Commercial, as vertical agreement under Section 1, Sherman Act, **§ 5:9**

BRILL, JULIE
"A Common Goal: The U.S. Federal Trade Commission's Healthcare Enforcement Program and its Implications for ACOs," text of remarks by Julie Brill, Commissioner, FTC, before the Sixth Annual Accountable Care Organization Summit Preconference (June 17, 2015), **App. E110**
"Bending the Cost Curve: The View from the Federal Trade Commission," speech by Julie Brill, FTC Comm., **App. E75**
"Competition in Health Care Markets," text of remarks by Julie Brill, Commissioner, FTC, at 2014 Hal White Antitrust Conference (June 9, 2014), **App. E97**
North Carolina Bar Assoc., prepared remarks before, **App. E69**
"What's Past is Prologue: FTC's Competition and Consumer Protection Priorities," text of remarks by Julie Brill, Commissioner, FTC, before the ABA Fall Forum (Nov. 6, 2014), **App. E102**

BUREAU OF COMPETITION
Advisory opinion, guidance on requesting and obtaining, **App. D196**
"Antitrust Enforcement in Health Care: Proscription, Not Prescription," remarks by Deborah L. Feinstein, Director, Bureau of Competition, FTC before the Fifth National Accountable Care Organization Summit (June 19, 2014), **App. E98**

BUREAU OF COMPETITION —Cont'd
FTC Staff Advisory Opinion to Mesa County Physician Independent Practice Association (Nov. 6, 1997), **App. D76A**
Prepared slides of Jeffrey Schmidt, Director, before ABA Section of Antitrust Law 2007 Fall Forum "Critical Loss Analysis: A Merger Lawyer's View" (Nov. 16, 2007), **App. E44**
Statement of the Federal Trade Commission's Bureau of Competition on Guidelines for Merger Investigations (Dec. 11, 2002), **App. B3F**
"The Forward-Looking Nature of Merger Analysis," remarks by Deborah L. Feinstein, Director, Bureau of Competition, FTC (Feb. 6, 2014), **App. E96**

BURNS, TIMOTHY G.
FTC letter to Hon. Timothy G. Burns, Louisiana House of Representatives, concerning in-school dentistry regulation (May 1, 2009), **App. D125**

BUSINESS
See also Companies; Firms (this index)
As element of damage action, **§ 11:4**
Partial integration of functions. Joint Ventures (this index)

BUSINESS HEALTH COMPANIES, INC.
Advisory opinions
(Oct. 19, 1996), **App. D64**
(Oct. 18, 1996), **App. D70**

BUSINESS JUSTIFICATION
Legitimate, exclusive contracts and, **§ 14:9**

BUSINESS OF INSURANCE
As antitrust exemption, **§ 9:10**

BUSINESS REVIEW LETTER
Generally, **App. C et seq., App. C7, App. E20**

BUSINESS REVIEW LETTER —Cont'd
AdviNet, Inc., **App. C53**
Allergy & Asthma Consultants, Inc. (March 19, 1996), **App. C66**
Allied Colon and Rectal Specialists (July 1, 1996), **App. C69**
American Association of Ophthalmology, **App. C8**
American Heart Association, **App. C27**
American Heart Association Pharmaceutical Roundtable (Mar. 20, 1998), **App. C85**
American Hospital Association, **App. C5**
American Medical Association, **App. C7**
American Red Cross, **App. C21**
Baxalta, Emergent BioSolutions, Grifols Therapeutics, and CSL Plasma, **App. C105**
Baxter Healthcare Corporation, **App. C26**
Bay Area Business Group on Health, **App. C37**
Bone & Joint Center of Mobile, P.A. (Apr. 16, 1997), **App. C79**
California Chiropractic Association, **App. C36**
California Pharmaceutical Association, **App. C2**
Case Western Reserve University School of Medicine, **App. C30**
Central Virginia Health Systems Agency, **App. C9**
CEO Roundtable on cancer (Sept. 28, 2008), **App. C99**
Certificate-of-need regulation (Dec. 8, 2006), **App. C97**
Chicagoland Radiological Network, **App. C49**
Children's Healthcare, P.A. (March 1, 1996), **App. C62**
Cincinnati Regional Orthopaedic and Sports Medicine Associates, Inc. (CROSMA) (Oct. 4, 1996), **App. C74**
CVT Surgical Center and Vascular Surgery Associates of Baton Rouge (Apr. 16, 1997), **App. C80**
Danbury Surgical Associates, **App. C24**
December 2, 1986, **App. C20**
Demonstration Project, **App. C42**
Department of Justice. See entries throughout this topic
Dermatologists, review letter to Dr. Oswald L. Mikell regarding proposed network of, **App. C56**
Dermnet, Inc. (Dec. 5, 1995), **App. C59**
Des Moines Collaborative Provider Organization, Inc., **App. C44**
Diana West (May 25, 2004), **App. C96**
El Paso Surgical Group (July 24, 1996), **App. C71**
February 5, 2002, **App. E20**
First Priority Health (Nov. 3, 1997), **App. C84**
Gainsharing program, Greater New York Hospital Assoc., **App. C102**
Gales Rexall Drug, **App. C1**
Gastroenterology Associates, Ltd (July 7, 1997), **App. C82**
Georgia Preferred Podiatric Medical Network (Nov. 3, 1995), **App. C58**
GI Associates, P.C. (July 7, 1997), **App. C82**
Hanger Orthopedic Group, Inc. (Sept 15, 1995), **App. C55**
Health and Personal Care Distribution Conference, Inc., **App. C34**
Health Care Management Associates, **App. C14**
Heritage Alliance and Lackawanna Physicians Organization (Sept. 15, 1998), **App. C86**
Hillhaven Corp., **App. C51**
Home Care Alliance, Inc. (Oct. 4, 1996), **App. C73**
Hospice Network of New Jersey, Inc. (April 24, 1996), **App. C67**

BUSINESS REVIEW LETTER —Cont'd
Hospital Corporation of America, **App. C15**
Hotel Employees and Restaurant Employees International Union Welfare Fund, **App. C41**
Houston Health Care Coalition, **App. C39**
Hyatt Imler Ott & Blount, P.C., **App. C28**
Independent Drug Wholesalers Group, **App. C23**
International Chiropractors Association, **App. C3**
International Chiropractor's Association of California, **App. C46**
Itasca Clinic and Grand Rapids Medical Associates (March 19, 1996), **App. C65**
Lexecon Health Service, **App. C17**
Linen Systems for Healthcare, LLC (Aug. 8, 2006), **App. C95**
March 9, 1979, **App. C7**
Marin General Hospital (Feb. 11, 1997), **App. C77**
Maryland Health Care Coalition, **App. C11**
Memorial Health, Inc. (Sept. 4, 2009), **App. C100**
Michigan Hospital Group, Inc. (April 2, 2002), **App. C93**
Mid-South Health Plan, **App. C52**
Midwest Behavioral Health LLC (Feb. 4, 2000), **App. C90**
Morros & Associates, **App. C6**
National Cardiovascular Network, Inc., **App. C32**
New Jersey Hospital Association, **App. C38**
North Mississippi Health Services, **App. C22**
Northwestern National Life Insurance Company, **App. C50**
NSM Purchasing Association (Jan. 13, 1999), **App. C88**
Ohio Hospital Purchasing Consortium, **App. C13**

BUSINESS REVIEW LETTER —Cont'd
Oklahoma Physicians Network-IPA, Inc. (Jan. 17, 1996), **App. C61**
Olympus America, Inc. (Aug. 29, 2001), **App. C92**
Orange Los Angeles Medical Group, Inc. (March 8, 1996), **App. C64**
Orthopaedic Associates of Mobile, P.A. (Apr. 16, 1997), **App. C79**
Pacific Business Group on Health (Apr. 26, 2010), **App. C101**
Pennsylvania Insurance Commissioner, **App. C31**
Pennsylvania Orthotics & Prosthetics Enterprise, **App. C54**
Pharmaceutical Care Network, **App. C18**
Pharmaceutical Manufacturers Association, **App. C33**
Physician Care, Inc., **App. C47**
Plastic Surgery Associates of Connecticut, LLC (June 28, 1996), **App. C68**
PPE collaboration, **App. C104**
Preferred Laboratory Access Network (Dec. 7, 1995), **App. C60**
Preferred Physicians Medical Group (July 23, 1999), **App. C89**
Preferred Podiatric Network Inc., **App. C45**
Primary and Specialist Medical Center, LLC (July 2, 1996), **App. C70**
PROklahoma Care, Inc. (Jan. 17, 1996), **App. C61**
Pulmonary Associates, Ltd., and Albuquerque Pulmonary Consultants, P.A., **App. C48**
Relating to Wisconsin Rate Review Program, **App. C4**
Rio Grande Eye Associates, P.A., **App. C91**
Ross Hospital (Feb. 11, 1997), **App. C77**
RWHC Network, Inc. (Nov. 12, 1996), **App. C76**
Santa Fe, New Mexico Managed Care Organization, Inc. (Sept. 16, 1998), **App. C87**

BUSINESS REVIEW LETTER —Cont'd
Sante Fe, New Mexico Managed Care Organization, Inc. (Feb. 12, 1997), **App. C78**
Seeskin, Paas, Blackburn & Co., **App. C43**
Service For You, **App. C19**
Sierra CommCare, Inc. (Aug. 15, 1996), **App. C72**
South Carolina State Health Planning Committee, concerning certificate-of-need regulation (Dec. 8, 2006), **App. C97**
Southern Health Corporation (March 5, 1996), **App. C63**
Southwestern Michigan Health Systems Agency, **App. C12**
Southwest Oncology Group (Nov. 2, 1995), **App. C57**
Southwest Orthopedic Specialists (June 10, 1997), **App. C81**
St. Anthony Medical Center, **App. C35**
Stark County Health Care Coalition, **App. C16**
St. Joseph's/Candler Health System (Sept. 4, 2009), **App. C100**
St. Louis Area Business Health Coalition, **App. C25**
Terence L. Smith, M.D. (Oct. 17, 1996), **App. C75**
To Senator Howard Metzenbaum, **App. C40**
Transplant Associates, **App. C29**
Valley Gastroenterologists (July 7, 1997), **App. C82**
Vermont Physicians Clinic (July 30, 1997), **App. C83**
Washington State Medical Association, **App. C94**
Westlake Health Campus Association, **App. C10**

BUSINESS REVIEW LETTERS: DEPARTMENT OF JUSTICE
Generally, **App. C**

BUSINESS REVIEW PROCEDURE
Of Antitrust Division enforcement, **§ 10:6, App. B4**

CALIFORNIA CHIROPRACTIC ASSOCIATION
Business review letter, **App. C36**

CALIFORNIA MANAGED IMAGING MEDICAL GROUP, INC.
Advisory opinion, **App. D39**

CALIFORNIA PHARMACEUTICAL ASSOCIATION
Business review letter, **App. C2**

CANADA
Dental licenses, FTC staff comment on New York's proposal to allow licensure by endorsement of Canadian, **App. D194**

CANCER
Business Review Letter to CEO Roundtable on clinical trials for cancer treatments (Sept. 28, 2008), **App. C99**

CAPACITY
To conspire, practitioner credentialing and, Section 1 of Sherman Act, **§ 13:11**

CAREMARK RX/ADVANCEPCS MERGER
FTC statement in closing investigation of (Feb. 11, 2004), **App. E29**

CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE
Business review letter, **App. C30**

CAUSATION
As element of damage action, **§ 11:5**

CENTERS FOR MEDICARE AND MEDICAID SERVICES
Medicare prescription drug benefit programs, FTC Staff Advocacy Letter to CMMS concerning any-willing-provider changes (Mar. 7, 2014), **App. D159**

CENTRAL TEXAS MEDICAL GROUP
Advisory opinions (Sept. 28, 1995), **App. D56**

CENTRAL VIRGINIA HEALTH SYSTEMS AGENCY
Business review letter, **App. C9**

CEO ROUNDTABLE
Business Review Letter to the CEO Roundtable on cancer (Sept. 28, 2008), **App. C99**

CERTIFICATE-OF-NEED (CON)
Agency opposition, **§ 22:3**
Alaska Senate Committee on Labor and Commerce, Certificate-of-Need Laws and SB 62, statement of FTC (Feb. 6, 2018), **App. E119**
Antitrust ramifications of certificate-of-need proceedings, **§ 22:4**
''Competition in healthcare and certificate of need'' prepared testimony of U.S. Department of Justice Antitrust Division to Georgia General Assembly (Feb. 23, 2007), **App. E39**
Federal Trade Commission prepared statement before Alaska House of Representatives (Feb. 15, 2008), **App. E45**
Federal Trade Commission prepared statement before Florida State Senate (Apr. 2, 2008), **App. E46**
Federal Trade Commission Staff advocacy letter concerning bill to modify North Carolina law (July 10, 2015), **App. D169**
FTC and Antitrust Division joint statement to Alaska House of Representatives, (Apr. 7, 2017), **App. D189**
FTC statement to Alaska Senate on CON laws and Bill 62 (Feb. 6, 2018), **App. D192**
Letter from Joseph Miller, Assistant Chief, Antitrust Division, to Sen. Michael D. Bishop, Michigan Senate Majority Leader, concerning proposed standards

CERTIFICATE-OF-NEED (CON) —Cont'd
(June 6, 2008), **App. C98**
Letter from U.S. Department of Justice Antitrust Division to South Carolina State Health Planning Committee concerning regulation (Dec. 8, 2006), **App. C97**
Physician-owned facilities, hospital's opposition, **§ 18:3**
Pros and cons, **§ 22:3**
South Carolina, joint statement of FTC and Antitrust Division on Certificate-of-Need laws and proposed legislation (Jan. 16, 2016), **App. D174**
Virginia, joint statement of FTC and Antitrust Division to Virginia Certificate of Need Work Group (Oct. 26, 2015), **App. D172**

CERTIFICATE OF PUBLIC ADVANTAGE
''A Health Care Check on COPAs; Assessing the Impact of Certificates of Public Advantage in Health Care Markets'' Joseph J. Simons, remarks, (June 18, 2019), **App. E127**
FTC Staff advocacy letter to Malaka Watson, Tennessee Department of Health, concerning cooperative agreements and certificates of public advantage (Sept. 24, 2015), **App. D171**

CERTIFICATES OF PUBLIC ADVANTAGE
FTC policy, **App. D200**

CHILDREN'S HEALTHCARE, P.A.
Business review letter (March 1, 1996), **App. C62**

CHINA
''Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission,'' Joshua D. Wright before the ABA Section of International Law Conference, Beijing, China (Sept. 16,

CHINA—Cont'd
2013), **App. E88**

CINCINNATI REGIONAL ORTHOPAEDIC AND SPORTS MEDICINE ASSOCIATES, INC. (CROSMA)
Business review letter (Oct. 4, 1996), **App. C74**

CIVIL ANTITRUST INVESTIGATION BASICS
(Speech), **App. E13**

CIVIL ENFORCEMENT
See also Enforcement (this index)
By Antitrust Division, **§ 10:4**

CLAYTON ACT
100th anniversary, ''Origin of the Species: The 100 Year Evolution of the Clayton Act,'' text of remarks of William J. Baer, Assistant Attorney General, Antitrust Division, before the ABA Clayton Act 100th Anniversary Symposium (Dec. 4, 2014), **App. E103**
Section 7
generally, **§ 8:1**
Antitrust Division and Federal Trade Commission, **§ 8:18**
conclusion, **§ 8:20**
conglomerate mergers, **§ 8:15**
diversification and, **§ 17:7**
joint ventures, **§ 8:16**
mergers and, **§ 15:3**
preliminary issues, **§ 8:2**
premerger notification requirements, **§ 8:17**
relevant markets, **§ 8:4**
2010 merger guidelines and merger analysis, **§ 8:3**
vertical mergers, **§ 8:14**
Section 8, **§ 7:12**
Section 7A, Hart Scott-Rodino premerger notification filings
revised jurisdictional thresholds, **App. B26**
Section 7A, premerger notification form and instructions under

CLAYTON ACT—Cont'd
amended, **App. B3**
Section 7: horizontal mergers
generally, **§ 8:5**
collusion, market characteristics and ease of, **§ 8:10**
concentration, **§ 8:6**
defenses, **§ 8:13**
efficiencies from merger, **§ 8:12**
financial viability, **§ 8:11**
guidelines, Department of Justice and Federal Trade Commission, **§ 15:9, App. B1**
other factors, **§ 8:7**
Section 2. Robinson-Patman Act (this index)
Text of, excerpts, **App. A2**

CLINICAL INTEGRATION
''Clinical Integration: The Changing Climate and What It Means for Care Coordination'' (Apr. 27, 2009), remarks of Pamela Jones Harbour, Commissioner, FTC, **App. E51**
Provider-controlled contracting networks, ancillary price-fixing agreements and clinical integration, **§ 20:8**
TriState Health Partners, FTC letter not to recommend challenge of proposed ''clinical integration'' of members' provision of health care services (Apr. 13, 2009), **App. D124**

CLINICAL TRIAL AGREEMENT
Business Review Letter to CEO Roundtable on cancer (Sept. 28, 2008), **App. C99**

COLLABORATION GUIDELINES
Antitrust guidelines for collaborations among competitors, **§ 3:14**
Medical school collaboration agreements, FTC Staff Advocacy letter to Alabama State Senate concerning antitrust exemption (May. 2, 2016), **App. D181**
Overview of, **§ 16:6**

COLLABORATION GUIDELINES —Cont'd
State-action protection to certain collaborative activity, FTC Staff Advocacy letter to West Virginia House of Delegates concerning (Mar. 9, 2016), **App. D178**

COLLECTIVE BARGAINING
FTC staff letter to Hon. William J. Seitz, Ohio State Senator, concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D120**
Legislative exemption, letter from FTC to Insurance Committee, Ohio House of Representatives, **App. D93**

COLLECTIVE NEGOTIATION OF FEES
FTC Staff letter to Puerto Rico Treasury and Financial Affairs Committee objecting to bill permitting health-care providers to collectively negotiate fees (Jan. 30, 2008), **App. D118**

COLUMBINE FAMILY HEALTH CENTER
Advisory opinions (Nov. 8, 1995), **App. D57**

COLUMBUS HOSPITAL
Advisory opinions (June 28, 1996), **App. D63**

"COMBINATION AND COLLABORATION IN HEALTH CARE MARKETS: ANTITRUST AS A CONSTRAINT IN A TIME OF CHANGE"
Speech, **App. E5**

COMMERCIAL BRIBERY
As vertical agreement under Section 1, Sherman Act, **§ 5:9**

COMMUNITY AND PAYER MORAL SUASION
Physician-owned facilities, **§ 18:3**

COMMUNITY CAREPARTNERS
Federal Trade Commission (FTC), staff advisory opinion to Community CarePartners concerning the Non-Profit Institutions Act, **App. D128**

COMMUNITY HOSPITAL, INC.
Advisory opinions (Dec. 22, 1997), **App. D77**

COMMUNITY PHARMACY FAIRNESS ACT
Prepared Statement of FTC Before U.S. House of Representatives Judicial Committee concerning HR 971, ''Community Pharmacy Fairness Act of 2007'' (Oct. 18, 2007)—David Wales, Bureau of Competition, **App. E43**

COMPANIES
See also Business (this index)

COMPETITION
See more specific entries throughout this index

COMPETITIVE BIDDING
Agreements not to engage in, ethical restraints on, **§ 24:4**

COMPETITIVE EFFECTS
Under Section 2(a), Robinson-Patman Act, **§ 7:5**

COMPETITIVELY SENSITIVE HEALTH CARE INFORMATION
Federal Trade Commission advocacy letter to Minnesota House of Representatives regarding a bill to permit disclosure (June 29, 2015), **App. D168**

COMPETITIVE MARKETPLACE
Summary report, FDA/FTC workshop for biosimilars, **App. D203**

COMPETITOR IDENTIFICATION
Mergers and, **§ 15:12**

CONCENTRATION
Mergers and
as factor in horizontal merger under Section 7 of Clayton Act, **§ 8:6**

CONFLICTS OF INTEREST
Physician-owned facilities, **§ 18:2, § 18:3**

CONGLOMERATE MERGERS
Under Section 7 of Clayton Act, **§ 8:15**

CONNECTICUT BAR ASSOCIATION
''Health Care Technology: Promoting Competition and Protecting Innovation,'' Maureen K. Ohlhausen, Commissioner of FTC, before Connecticut Bar Association Antitrust amp: Trade Regulation and Consumer Law Sections (Feb. 26, 2014), **App. E94**

CONNECTICUT HOSPITAL ASSOCIATION
Advisory opinions (Dec. 20, 2001), **App. D89**

CONSENT ORDER
Amgen Inc. and Horizon Therapeutics plc, FTC File No. DO9414, **App. G16**
Aurobindo Pharma LTD, Aurobindo USA Inc., and Lannett Company, Inc., **App. F19**
agreement containing consent order, **App. F20**
Caremark Rx, LLC and Zinc Health Services, LLC, agreement containing, **App. F16**
In the Matter of (Insulin) Caremark Rx, Zinc Health Services, et al., agreement containing, express scripts defendants, **App. F14**
In the Matter of Centerbridge Seaport Acquisition Fund, L.P., agreement containing, **App. F13**

CONSPIRACY
See also Agreements (this index)

CONSPIRACY—Cont'd
Capacity to conspire, practitioner credentialing and, under Section 1, Sherman Act, **§ 13:11**
In fact, practitioner credentialing and, under Section 1 of Sherman Act, **§ 13:12**
To monopolize, **§ 6:16**

CONSUMER
Competition Policy and Consumer Rights Oversight of the Enforcement of the Antitrust Laws, **App. E146**
''Interface of Competition and Consumer Protection'' (October 31, 2002), **App. E23**

CONTRACTS
Exclusive. Exclusive Contracts (this index)
Networks. Provider-Controlled Contracting Networks (this index)

COOPERATIVE AGREEMENTS
FTC Staff advisory letter to Susan Puglisi, Virginia Department of Health, concerning cooperative agreements (Sept. 17, 2015), **App. D170**
FTC Staff advocacy letter to Malaka Watson, Tennessee Department of Health, concerning cooperative agreements and certificates of public advantage (Sept. 24, 2015), **App. D171**

CORONAVIRUS
DOJ and FTC joint antitrust statement regarding COVID-19 (March 2020), **App. G4**

"COST-SHIFTING"
Physician-owned facilities, **§ 18:2**

COVENANTS
Horizontal, not to compete, under Section 1 of Sherman Act, **§ 4:6**

COVID-19
DOJ and FTC joint antitrust statement regarding COVID-19

COVID-19—Cont'd
(March 2020), **App. G4**

CREDENTIALING
Practitioner Credentialing (this index)

CREDIT SUISSE 2018 WASHINGTON PERSPECTIVES CONFERENCE
Remarks at, (Jan. 10, 2018), **App. E124**

CRIMINAL ENFORCEMENT
See also Enforcement (this index)
By Antitrust Division, **§ 10:3**

CROSS-MARKET
Mergers, **§ 15:29**

"CROSS-SUBSIDIZATION"
Physician-owned facilities, **§ 18:2**

"CURRENT ISSUES IN HEALTH CARE ANTITRUST ENFORCEMENT AT FTC"
(Speech), **App. E14**

CVT SURGICAL CENTER AND VASCULAR SURGERY ASSOCIATES OF BATON ROUGE
Business review letter (Apr. 16, 1997), **App. C80**

DAMAGES
Private actions, **§ 11:1**

DANBURY SURGICAL ASSOCIATES
Business review letter, **App. C24**

DEAL
Refusals to Deal (this index)

DEALING AGREEMENTS
Under Section 1, Sherman Act
exclusive dealing, **§ 5:7**
reciprocal dealing, **§ 5:8**

DEFENSES
Damage action
generally, **§ 11:9**

DEFENSES—Cont'd
Damage action—Cont'd
antitrust defenses in nonantitrust cases, **§ 11:12**
in pari delicto and related defenses, **§ 11:11**
statute of limitations, **§ 11:10**
Mergers, failing company, **§ 15:20**
To horizontal mergers under Section 7 of Clayton Act, **§ 8:13**
Under Section 2(a), Robinson-Patman Act, **§ 7:6**

DELAWARE
Board of Dietetics/Nutrition, Telehealth Dietetic and Nutrition Services), FTC staff advocacy letter (Aug. 16, 2016, **App. D185**
Board of Occupational Therapy Practice, occupational therapist telehealth supervision, FTC staff advocacy letter (Aug. 3, 2016), **App. D184**
Board of Speech/Language Pathologists, Audiologists, and Hearing Aid Dispensers, amendment to telecommunication and telehealth regulations, FTC advocacy letter (Nov. 29, 2016), **App. D186**

DENIAL OF ACCESS
To essential facility, as anticompetitive conduct under Section 2 of Sherman Act, **§ 6:8**

DENTISTS AND ORAL SURGEONS
Canadian dental licenses, FTC staff comment on New York's proposal to allow licensure by endorsement of, **App. D194**
Dental Accreditation Commission, **App. D156, App. D158, App. D162**
Education accreditation standards
modifications to Louisiana Rules regarding the practice of portable and mobile dentistry, FTC Staff comments to Louisiana State Board of Dentistry (Dec. 9, 2009), **App. D126**

DENTISTS AND ORAL SURGEONS —Cont'd
Education accreditation standards —Cont'd
Staff advocacy letter to Sherin Tooks, Commission on Dental Accreditation (Dec. 12, 2014), **App. D162**
Staff letter to Commission on Dental Accreditation (Dec. 2, 2013), **App. D156, App. D158**
In-school dentistry regulation, FTC letter to Hon. Timothy G. Burns, Louisiana House of Representatives (May 1, 2009), **App. D125**
Practices, business organizations supporting, **App. D148**
Southwest Florida Oral Surgery Associates (Dec. 2, 1996), advisory opinions, **App. D65**
Supervision of dental hygienists, Advocacy letter to Georgia State Senate (Jan. 29, 2016), **App. D175**
Therapist licensing, staff advocacy letter (Mar. 3, 2017), **App. D187**
Utah Society of Oral and Maxillofacial Surgeons, advisory opinions, **App. D14**

DENTURISTS
FTC Advocacy letter to Kentucky House of Representatives concerning regulation (Mar. 25, 2016), **App. D180**

DEPARTMENTAL CLOSINGS
Exclusive contracts and, **§ 14:14**

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FTC Staff advocacy letter to Department of Health and Human Services concerning interoperability of health information technology (Apr. 3, 2015), **App. D163**

DEPARTMENT OF JUSTICE
Additional information, documentary material request, **App. B9**

DEPARTMENT OF JUSTICE —Cont'd
Antitrust Division, Price Fixing, Bid Rigging, and Market Allocation Schemes
what they are and what to look for, antitrust primer, **App. G47**
Antitrust division. Justice Department (United States Department of Justice; Antitrust Division) (this index)
DOJ and FTC 2023 Merger Guidelines, **App. B20**
DOJ Complaint in matter of U.S., et al. v. Unitedhealth Group Incorporated, et al., **App. G29**
44th Hart-Scott-Rodino annual report, **App. D204**
Keynote remarks of Commissioner Rebecca Kelly Slaughter, Pharmaceutical Task Force Workshop, **App. E145**
Press release, FTC, DOJ and HHS work
lower health care and drug costs, **App. B21**
Strengthen enforcement against illegal mergers, **App. B19**

DERMATOLOGISTS
Business review letter to Dr. Oswald L. Mikell regarding proposed network of, **App. C56**

DERMNET, INC.
Business review letter (Dec. 5, 1995), **App. C59**

DES MOINES COLLABORATIVE PROVIDER ORGANIZATION, INC.
Business review letter, **App. C44**

"DIAGNOSING PHYSICIAN-HOSPITAL ORGANIZATIONS"
(Speech), **App. E28**

DIRTY TRICKS
Under Section 1 of Sherman Act, as horizontal agreements, **§ 4:9**

DISMISSAL
Summary Judgments (this index)

DISTRIBUTORSHIP TERMINATIONS
Under Section 1 of Sherman Act, as vertical agreements, **§ 5:4**

DIVERSIFICATION
Provider. Provider Diversification (this index)

DOJ ANTITRUST DIVISION
Economic analysis group discussion paper
Online Reviews and Hospital Choices, EAG 22-1 December 2022, **App. G13**

DUAL DISTRIBUTION
Under Section 1 of Sherman Act, as vertical agreements, **§ 5:5**

DUNCHEON, MICHAEL A.
Advisory opinion, **App. D20**

DUNLAP MEMORIAL HOSPITAL
FTC staff advisory opinion to (Jan. 6, 2004), **App. D103**

EASTERN OHIO PHYSICIANS ORGANIZATION, INC.
Advisory opinions (Sept. 28, 1995), **App. D55**

ECONOMIC CREDENTIALING
Physician-owned facilities, **§ 18:3**

ECONOMIC EFFECTS
Of mergers, **§ 15:2**

ECONOMIC INTEREST
In sale of tied product, exclusive contracts and, **§ 14:8**
Physician-Owned Facilities (this index)

ECONOMIC TOOLS
"FTC v. Sysco: Old School Antitrust With Modern Economic Tools" text of remarks of Deborah L. Feinstein before GCR Live (Sept. 18, 2015), **App. E112**

EDWARDS LIFESCIENCES CORP. AND GENESIS MEDTECH GROUP, LTD.
Competitive impact statement, **App. F18**
Proposed final judgment, **App. F17**

EFFICIENCIES
"Efficiencies and antitrust: an Ongoing Evolution" (November 8, 2002), **App. E24**
"Efficiency Justifications for Hospital Mergers" (speech), **App. E6**

EL PASO SURGICAL GROUP
Business review letter (July 24, 1996), **App. C71**

EMMER, TOM
FTC letter to Hon. Tom Emmer, Minnesota House of Representatives, concerning rural health care cooperatives joint negotiations (Mar 18, 2009), **App. D122**

ENFORCEMENT (ANTITRUST DIVISION AND FTC)
Generally, **§ 10:1**
Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E147**
Antitrust Division
generally, **§ 10:2**
business review procedure
generally, **§ 10:6**
see also Business review letter (this index)
civil enforcement, **§ 10:4**
criminal enforcement, **§ 10:3**
organization, **§ 10:2**
relief in civil cases, **§ 10:5**
Edith Ramirez, "Oversight of Enforcement of Antitrust Laws," before U.S. House of Representatives, Washington D.C. (Nov 15, 2003), **App. E92**

ENFORCEMENT (ANTITRUST DIVISION AND FTC)—Cont'd
Federal Trade Commission
generally, **§ 10:7**
advisory opinions
generally, **§ 10:9, App. B5**
see also Advisory Opinions (this index)
Government enforcement statements, **§ 1:7**
History of, in health care sector, **§ 1:6**
Joshua D. Wright, "Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission," before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E88**
J. Thomas Rosch, "Enforcement Strategies in the Health Care Industry," prepared remarks before the ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E48**
Maureen K. Ohlhausen, "When Regulation Protects Privilege Instead of People: Government Restraints of Trade-A Competition Enforcer's Perspective," text of remarks before The Antitrust Enforcement Symposium 2015 of Journal of Antitrust Enforcement (June 27, 2015), **App. E111**
"Oversight of the Enforcement of Antitrust Law," FTC prepared statement before U.S. Senate Committee on the Judiciary (Mar 9, 2016), **App. E117**
"Oversight of the Enforcement of Antitrust Laws," Edith Ramirez before U.S. House of Representatives, Washington D.C. (Nov 15, 2003), **App. E92**
Oversight of the Enforcement of the Antitrust Laws FTC prepared statement before US House of Representatives (May 15, 2015), **App. E108**

ENFORCEMENT (ANTITRUST DIVISION AND FTC)—Cont'd
Statements of enforcement policy and analytical principles relating to health care and antitrust, withdrawn, **App. F1**
Terrell McSweeney, "Reflections on an Active Year in Merger Enforcement," keynote remarks at Antitrust Law Leaders Forum (Feb. 5, 2016), **App. E116**

EQUIPMENT
Joint ventures among competitors to provide new, **§ 16:9**

EQUITABLE LIFE ASSURANCE SOCIETY OF THE UNITED STATES
Advisory opinion, **App. D21**

EQUITABLE RELIEF
In Federal Trade Commission, plaintiff, v. Surescripts, LLC
stipulated order, **App. G15**

ESSENTIAL FACILITY
Denial of access to, as anticompetitive conduct under Section 2 of Sherman Act, **§ 6:8**
Diversification and essential facilities doctrine, **§ 17:10**

ETHICAL RESTRAINTS
Generally, **§ 24:1**
Agreements not to engage in competitive bidding, **§ 24:4**
Conclusion, **§ 24:10**
Employee non-compete agreements, **§ 18:4**
Generally applicable antitrust principles, **§ 24:2**
Limitations on advertising and solicitation, **§ 24:6**
Membership restrictions, **§ 24:8**
"Poaching," limitations on, **§ 24:5**
Price-fixing agreements, **§ 24:3**
Restraints on practice form, **§ 24:7**
Standards of practice relating to quality, **§ 24:9**

"EXAMINING COMPETITION IN GROUP HEALTH CARE"
Prepared Statement of FTC Before U.S. Senate Committee on Judiciary, (Sept. 6, 2006), **App. E37A**

EXCLUSIONARY CONDUCT
See also Anticompetitive Conduct (this index)
Unreasonably, as anticompetitive conduct under Section 2 of Sherman Act, **§ 6:12**

EXCLUSION FROM FACILITY
Practitioner Credentialing (this index)

EXCLUSION PAYMENT SETTLEMENTS
''Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry; Why Consumers and the Federal Government are Paying Too Much for Prescription Drugs,'' prepared statement of FTC before Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate (June 3, 2009)—Richard A. Feinstein, Director, Bureau of Competition, **App. E50**
''Exclusion Payments to Settle Pharmaceutical Patent Cases: They're B-a-c-k!,'' prepared remarks before second annual in-house counsel's forum on pharmaceutical antitrust (Apr. 24, 2006), **App. E36**
''FTC v. Actavis and the Future of Reverse Payment Cases,'' remarks of Joshua D. Wright, Commissioner, FTC, before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E90**
''How Pay-for-Delay Settlements Make Consumers and Federal Government Pay More for Much Needed Drugs,'' prepared statement of J. Thomas Rosch, Commissioner, FTC, before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives (Mar. 31, 2009), **App. E49**
Pay-for-Delay Settlements
generally, **25:1, 25:2**
Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E54**
recent cases, **25:2**

EXCLUSIVE CONTRACTS
Health plan market power, **§ 21:9**
Hospital/physician. Exclusive Contracts (Hospital/Physician) (this index)
Physician-owned facilities, **§ 18:3**

EXCLUSIVE CONTRACTS (HOSPITAL/PHYSICIAN)
Generally, **§ 14:1**
And vertical price-fixing agreements, **§ 14:15**
Antitrust theories, **§ 14:2**
As tying arrangements
generally, **§ 14:3**
conditional sale of one service on purchase of another, **§ 14:5**
economic interest in sale of tied product, **§ 14:8**
effect on substantial amount of interstate commerce, **§ 14:7**
legitimate business justification, **§ 14:9**
market power in market for tying product, **§ 14:6**
separate and distinct products, **§ 14:4**
As violations of Section 2 of Sherman Act, **§ 14:13**
Departmental closings, **§ 14:14**
Exclusive dealing agreements
generally, **§ 14:10**

EXCLUSIVE CONTRACTS (HOSPITAL/PHYSICIAN) —Cont'd
Exclusive dealing agreements —Cont'd
effect on competition, **§ 14:12**
relevant market, **§ 14:11**
Minimizing antitrust risk, **§ 14:16**

EXCLUSIVE DEALING AGREEMENTS (HOSPITAL/PHYSICIAN)
Generally, **§ 14:10**
As vertical agreements under Section 1 of Sherman Act, **§ 5:7**
Diversification resulting from, **§ 17:4**
Effect on competition, **§ 14:12**
Relevant market, **§ 14:11**

EXCLUSIVE JURISDICTION
Generally, **§ 9:6**

EXEMPTIONS AND IMMUNITIES
Generally, **§ 9:1**
Business of insurance, **§ 9:10**
Federal government and federally regulated industries
generally, **§ 9:3**
express immunity, **§ 9:4**
federal government immunity, **§ 9:3**
implied repeal, **§ 9:5**
primary and exclusive jurisdiction, **§ 9:6**
Health Care Quality Improvement Act, **§ 9:12**
Hospital medical staff credentialing, **§ 9:12**
Labor, **§ 9:11**
Local Government Antitrust Act, **§ 9:9**
Nonprofit entities and noncommercial conduct, **§ 9:2**
Physician peer-review activities, **§ 9:12**
Robinson-Patman Act, **§ 7:10**
Solicitation of government action, **§ 9:8**
State action, **§ 9:7**
from antitrust, **§ 9:7**

EXEMPTIONS AND IMMUNITIES —Cont'd
State action, **§ 9:7**—Cont'd
mergers, economic effects, **§ 15:6**
''Reflections on Supreme Court's North Carolina Dental Decision and the FTC's Campaign to Rein in State Action Immunity,'' Maureen K. Ohlhausen, Commissioner, (Mar 31, 2015), **App. E106**

EXPEDITED BUSINESS REVIEW REQUEST PURSUANT TO COVID-19 EXPEDITED PROCEDURE
Eli Lilly, AbCellera Biologics, Amgen, AstraZeneca, Genentech, and GSK, **App. C106**

EXPRESS IMMUNITY
From antitrust, **§ 9:4**

FACILITY
Denial of access to essential, as anticompetitive conduct under Section 2 of Sherman Act, **§ 6:8**

FEDERAL COMPLAINT FOR INJUNCTION
FTC v. U.S. Anesthesia Partners, Inc., **App. G17**

FEDERAL GOVERNMENT
And federally regulated industries. Exemptions and Immunities (this index)

FEDERAL TRADE COMMISSION (FTC)
For detailed matters, see more specific entries throughout this index
Accountable Care Organizations, **§ 20:15**
Accountable Care Organizations participating in Medicare Shared Savings Program, **App. E82**
Administrative Complaint
Matter of GTCR BC Holdings, LLC and Surmodics, Inc
FTC Matter/File Number 241 0095, Docket Number

FEDERAL TRADE COMMISSION (FTC)—Cont'd
Administrative Complaint—Cont'd
Matter of GTCR BC Holdings, LLC and Surmodics, Inc —Cont'd
9440, **App. G32**
Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E147**
Advanced practice registered nurses, advocacy letter regarding, **App. D153, App. D164, App. D176**
''Advancing Economic Liberty,'' **App. E120**
Advisory opinions of
for detailed matters, see Advisory Opinions (this index)
generally, **§ 10:9**
Affiliation agreement, close of investigation of, **App. E74**
''A Health Care Check on COPAs; Assessing the Impact of Certificates of Public Advantage in Health Care Markets'' Joseph J. Simons, (June 18, 2019), **App. E127**
Alabama State Board of Medical Examiners, FTC staff comments concerning proposed regulation of interventional pain management services, **App. D130**
Alaska House of Representatives, prepared statement of FTC concerning certificate of need (Feb. 15, 2008), **App. E45**
Alaska Senate Committee on Labor and Commerce, Certificate-of-Need Laws and SB 62, statement of FTC (Feb. 6, 2018), **App. E119**
Amicus brief, Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals, **App. D202**
Annual report, 44th Hart-Scott-Rodino, **App. D204**
''Antitrust Analysis of Reverse Payments After Actavis: Three Questions and Proposed Answers,'' text of remarks of Joshua D. Wright, Commissioner, FTC, before the ABA Master Course VII (Oct. 10, 2014), **App. E101**
Appeal procedure for requests for additional information, **App. B8**
Assistant attorney general Jonathan Kanter announces task force on health care monopolies and collusion (May 9, 2024), **App. G23**
Attempted merger of Rhode Island's largest healthcare providers, **App. E141**
''Bigger than Big Tech, The Need to Reform Our Health Care Markets Using Choice and Competition'' Christine S. Wilson, (September 9, 2019), **App. E128**
Bureau of Competition. Bureau of Competition (this index)
Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E29**
Certificate-of-need
Alaska Senate Bill 62 (Feb. 6, 2018), **App. D192**
Alaska Senate Committee on Labor and Commerce, Certificate-of-Need Laws and SB 62, statement of FTC (Feb. 6, 2018), **App. E119**
application, advocacy letter, **App. D190**
laws and Alaska, joint statement of FTC and Antitrust Division (Apr. 7, 2017), **App. D189**
laws and Alaska Senate Bill 62 (Feb. 6, 2018), **App. D192**
Certificates of Public Advantage, advocacy letter regarding, **App. D165**
Certified nurse practitioners, advocacy letter, **App. D191**

FEDERAL TRADE COMMISSION (FTC)—Cont'd
Chronic pain treatment by certified registered nurse anesthetists, **App. D154**
"Clinical Integration: The Changing Climate and What It Means for Care Coordination" (Apr. 27, 2009), remarks of Pamela Jones Harbour, Commissioner, FTC, **App. E51**
Collaborative activity, FTC Staff Advocacy letter to West Virginia concerning state-action protection (Mar. 9, 2016), **App. D178**
Collaborative practice agreements between advanced practice registered nurses and physicians, **App. D147**
Competition in health care markets, text of remarks regarding, **App. E84**
Competition Policy and Consumer Rights Oversight of the Enforcement of the Antitrust Laws, United States Senate Committee on the Judiciary Subcommittee on Antitrust, **App. E146**
Competitively sensitive health care information, advocacy letter regarding a bill to permit disclosure, **App. D168**
Competitive marketplace for biosimilars, FDA/FTC workshop, **App. D203**
Concurring statement of commissioner Andrew N. Ferguson regarding the pharmacy benefit managers interim staff report (July 9, 2024), **App. G22**
Connecticut General Assembly, letter concerning bill to establish provider cooperative care arrangements, **App. D140**
"Death by a Thousand Haircuts: Economic Liberty and Occupational Licensure Reform," **App. E121**
Delaware (this index)
Dentists and Oral Surgeons (this index)

FEDERAL TRADE COMMISSION (FTC)—Cont'd
Denturists regulation, FTC Advocacy letter to Kentucky House of Representatives (Mar. 25, 2016), **App. D180**
Divestiture of locations to address concerns regarding proposed acquisition, **App. E79**
DOJ and FTC Antitrust Guidelines for Business Activities Affecting Workers
(January 2025), **App. G34**
DOJ and FTC 2023 Merger Guidelines, **App. B20**
DOJ Antitrust Division, Economic analysis group discussion paper
Online Reviews and Hospital Choices, EAG 22-1 December 2022, **App. G13**
"Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care," text of remarks of Martin Gaynor, Director, Bureau of Economics, FTC, before the 2014 American Antitrust Institute Annual Conference, **App. E100**
Eliminating certain occupational licensing requirements, staff advocacy letter (Mar. 15, 2017), **App. D188**
Enforcement against illegal mergers, **App. B19**
Enforcement by
generally, **§ 10:7**
see also Enforcement (this index)
FDA draft guidance biosimilar drugs comment letter (August 20, 2024), **App. G24**
FDA/FTC workshop on a competitive marketplace for biosimilars, **App. D203**
Florida House of Representatives, letter concerning regulation of advanced registered nurse practitioners, **App. D135**
44th Hart-Scott-Rodino annual report, **App. D204**

FEDERAL TRADE COMMISSION (FTC)—Cont'd
FTC amicus brief
re Bystolic Antitrust Litigation, **App. D206**
Georgia Board of Dentistry, FTC comments concerning proposed amendments to rules governing supervision of hygienists, **App. D131**
Hart-Scott-Rodino annual report, 44th, **App. D204**
Health care hospitals collaboration, advocacy letter regarding authorization, **App. D167**
Health care information exchanges, advocacy letter regarding proposed antitrust immunity, **App. D166**
''Health Care Technology: Promoting Competition and Protecting Innovation,'' Maureen K. Ohlhausen, Commissioner, before Connecticut Bar Association Antitrust amp: Trade Regulation and Consumer Law Sections (Feb. 26, 2014), **App. E94**
Health information technology, advocacy letter regarding interoperability, **App. D163**
''Hospital Consolidation: The Good, The Bad, and The Ugly,'' **App. E81**
HSR, FAQ, **App. B12**
HSR premerger, withdrawal and refiling, **App. B13**
Human resource professionals, DOJ and FTC antitrust guidance (Oct. 2016), **App. G3**
Illinois State Senate, letter concerning limiting chronic pain treatment by certified registered nurse anesthetists, **App. D154**
''Importance of Competition and Antitrust Enforcement to Lower-Cost, Higher-Quality Health Care'' Prepared Statement of FTC before Senate Subcommittee on Consumer Protection, Product Safety, and Insurance

FEDERAL TRADE COMMISSION (FTC)—Cont'd
(July 16, 2009), **App. E53**
In re Davita, proposed order, re-instituted use of prior approval provisions in merger orders, **App. B18**
Interim staff report on pharmacy benefit managers
the powerful middlemen inflating drug costs and squeezing main street pharmacies (July 2024), **App. G19**
J. Thomas Roche, letter concerning antitrust ramifications of accountable care organizations, **App. D133**
J. Thomas Rosch, Antitrust/Intellectual Property Interface, **App. E59**
Kentucky Cabinet for Health and Family Services, FTC staff comments concerning proposed rule to regulate limited service clinics, **App. D129**
Kentucky State Senate, letter concerning bill relating to advanced practice registered nurses scope of practice, **App. D145**
Keynote remarks of Commissioner Rebecca Kelly Slaughter, Pharmaceutical Task Force Workshop, **App. E145**
Lifespan Corporation and Care New England Health System, statement, **App. E140**
''Looking Back to Move Forward: Preserving the Progressive Tradition at the FTC,'' **App. E80**
Louisiana State Representatives, letter concerning Registered Nurse Collaborative Agreements (Apr. 20, 2012), **App. D147**
Maine Board of Dental Examiners, letter concerning proposed rule to limit x-ray procedures by dental hygienists, **App. D144**
Massachusetts House of Representatives, letter concerning removal of supervision requirement from

FEDERAL TRADE COMMISSION (FTC)—Cont'd
nurse practitioners and nurse anesthesiologists (Jan. 17, 2014), **App. D157**
Medical school collaboration agreements, letter to Alabama State Senate concerning antitrust exemption for public university medical school agreements (May. 2, 2016), **App. D181**
Medicare Prescription Drug Benefit Programs, Staff Advocacy Letter to Centers for Medicare and Medicaid Services concerning any-willing-provider changes (Mar. 7, 2014), **App. D159**
Memorandum to staff concerning merger investigations, **App. B3E**
Mergers and
generally, **§ 15:3**
Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E29**
consent orders, FAQ, **§ 15:36**
guidelines on horizontal mergers, **§ 15:9**
''Retrospectives at the FTC: Promoting an Antitrust Agenda,'' text of remarks of Edith Ramirez before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E99**
staff letter to Louisiana attorney general concerning Tenet Healthcare Corporation's proposed acquisition of Slidell Memorial Hospital (Apr. 1, 2003), **App. D99**
statement on horizontal mergers (1982), **App. B2**
Mergers and guidelines on horizontal mergers, **App. B1**
Minnesota House of Representatives, FTC Staff advocacy letter regarding bill to permit

FEDERAL TRADE COMMISSION (FTC)—Cont'd
disclosure of competitively sensitive health care information, **App. D168**
Mississippi House of Representatives, letter concerning regulation of pharmacy benefit managers, **App. D136**
Missouri House of Representatives, letter concerning bill relating to CRNA scope of practice, **App. D146**
Multilateral pharmaceutical merger task force, Commissioner statement, **App. E135**
Multilateral pharmaceutical merger task force, public input, press release, **App. D197**
New Jersey Hospital Networks merger, **App. E142**
New York, staff comment on proposal to allow licensure by endorsement of Canadian dental licenses, **App. D194**
New York Senate, comment concerning regulation of mail-order pharmacies, **App. D141**
New York Senate, letter concerning bill to permit collective negotiations among providers, **App. D143**
New York State Assembly, FTC Staff advocacy letter regarding authorization of health care hospitals collaboration, **App. D167**
Non-Profit Institutions Act
Community CarePartners, staff advisory opinion to, **App. D128**
Quest Analytics Group, staff advisory opinion to, **App. D160**
University of Michigan, staff advisory opinion to the, **App. D127**
Non-Profit Institutions Act, opinion concerning, **App. D150, App. D151**
Norman Physician Hospital Organization, Staff Advisory Opinion to, **App. D152**

FEDERAL TRADE COMMISSION (FTC)—Cont'd
North Carolina House of Representatives, FTC Staff advocacy letter concerning a bill to modify Certificate-of-Need law (July 10, 2015), **App. D169**
North Carolina Senate Bill 743
state action defense to UNC healths collaborative activities, **App. D205**
North Carolina State Board of Opticians, FTC staff comments concerning proposed regulations for optical goods and optical goods business, **App. D132**
Nurse practitioners and nurse anesthesiologists, Staff letter to Hon. Kay Khan, Massachusetts House of Representatives, concerning bill to remove supervision requirement (Jan. 17, 2014), **App. D157**
Office of Public Affairs Director, preliminary injunction halting New Jersey hospital merger, **App. E137**
Orange book, brand drug manufacturers improper listing of patents, statement, **App. B22**
Order to file a special report, **App. D198**
Oregon Legislature, FTC Staff advocacy letter concerning antitrust immunity for health care information exchanges (May 18, 2015), **App. D166**
''Oversight of Enforcement of Antitrust Law,'' prepared statement of FTC before U.S. Senate Committee on the Judiciary (Mar 9, 2016), **App. E117**
''Oversight of Enforcement of Antitrust Laws,'' Edith Ramirez before U.S. House of Representatives, Washington D.C. (Nov 15, 2003), **App. E92**
Overview of FTC actions in health care services and products (June 2026), **App. G5**

FEDERAL TRADE COMMISSION (FTC)—Cont'd
Overview of FTC actions in pharmaceutical products and distribution (June 2026), **App. G6**
Pay-for-delay deals, limiting competition and costing consumers, **App. E85**
''Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E54**
PBM related advocacy and current market realities reports, **App. D207**
Perspectives on Certificates of Public Advantage, **App. D200**
Petition
FTC v. Louisiana Childrens Medical Center, **App. G14**
Pharmaceutical merger enforcement program, Commissioner statement, **App. E134**
Pharmaceutical mergers, analysis examination, **App. G12**
Pharmaceutical Task Force Workshop, keynote remarks of Commissioner Rebecca Kelly Slaughter, **App. E145**
Physician collaboration, letter concerning proposed legislation, **App. D155**
Post-patent pharmaceutical markets, issues in, **App. E122**
Preliminary injunction
pursuant to Section 13(b) of the Federal Trade Commission Act, **App. G10**
Prepared Remarks Before ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E48**
Prepared Statement Before Committee of Small Business, U.S. House of Representatives on

FEDERAL TRADE COMMISSION (FTC)—Cont'd
"Competition and Potential Costs and Benefits of Professional Licensure" (Jul. 16, 2014), **App. E104**
Prepared Statement Before Florida State Senate on health care competition and Florida's certificate of need (CON) laws (Apr. 2, 2008), **App. E46**
Prepared Statement before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives on Pay-for-Delay Settlements (Mar. 31, 2009)—J. Thomas Rosch, Commissioner, FTC, **App. E49**
Prepared Statement before Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate on Anticompetitive Pay-for-Delay Settlements (June 3, 2009)—Richard A. Feinstein, Director, Bureau of Competition, **App. E50**
Prepared Statement Before U.S. Senate Committee on Judiciary, "Examining Competition in Group Health Care" (Sept. 6, 2006), **App. E37A**
Prepared Statement Before U.S. Senate Committee on the Judiciary, "License to Compete: Occupational Licensing and the State Action Doctrine" (Feb. 2, 2016), **App. E115**
Prepared Statement Before U.S. Senate Special Committee on Aging Concerning Barriers to Generic Entry (July 20, 2006), **App. E37**
Prepared Statement of FTC and Pharmaceutical Industry before Committee of Judiciary, US Senate (June 17, 2003)—Timothy J. Muris, Chairman, FTC, **App. E26**

FEDERAL TRADE COMMISSION (FTC)—Cont'd
Press release, FTC, DOJ and HHS work
lower health care and drug costs, **App. B21**
Primary service area shares under ACO policy statement, calculating, **App. E83**
Protecting competition in healthcare markets, **App. E123**
Provider-controlled contracting networks, Federal Trade Commission and Department of Justice Statement of Antitrust Enforcement Policy, **§ 20:15**
Quest Analytics Group, FTC Staff advisory opinion concerning Non-Profit Institutions Act (Mar. 7, 2014), **App. D160**
Requests for additional information, appeal procedure for, **App. B8**
"Retrospectives at the FTC: Promoting an Antitrust Agenda," text of remarks of Edith Ramirez, Chairwoman, before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E99**
Richard A. Feinstein statement to House committee on antitrust enforcement in the health care industry, **App. E60**
Second-request form letter, **App. B3H**
"Section 5: Principles of Navigation," Maureen K. Ohlhausen, Commissioner, before U.S. Chamber of Commerce, Washington, DC (July 25, 2013), **App. E86**
Sharis A. Pozen statement before Judiciary Committee on antitrust, competition policy, and consumer rights, **App. E61**
South Carolina House of Representatives, FTC advocacy letter concerning supervision of advanced practice nurses (Nov. 2, 2015), **App. D173**

FEDERAL TRADE COMMISSION (FTC)—Cont'd
South Carolina House of Representatives, joint statement of FTC and Antitrust Division on Certificate-of-Need laws and proposed legislation (Jan. 16, 2016), **App. D174**
Staff Comment
North Carolina Senate Bill 743, **App. D205**
Staff comment on New York's proposal to allow licensure by endorsement of Canadian dental licenses, **App. D194**
Staff comment to Washing State Rep. Paul Graves, S.S.B. 5411/H.B. 1473 (Feb. 9 2018), **App. D193**
Staff letter to Hon. Elaine Nekritz, Illinois State Representative, concerning proposed regulation of retail health care facilities (May 29, 2008), **App. D121**
Staff letter to Hon. William J. Seitz, Ohio State Senator, concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D120**
Staff letter to Louisiana attorney general concerning Tenet Healthcare Corporation's proposed acquisition of Sliddell Memorial Hospital (Apr. 1, 2003), **App. D99**
Staff letter to Louisiana State Representative Timothy G. Burns concerning in-house school dentistry (May 1, 2009), **App. D125**
Staff letter to Minnesota State Representative Tom Emmer concerning rural health care cooperatives joint negotiation (Mar. 18, 2009), **App. D122**
Staff letter to North Carolina representative concerning dental practice managers (May 25, 2012), **App. D148**
Staff letter to Ohio House of Representatives (Oct. 16, 2002), **App. D95**

FEDERAL TRADE COMMISSION (FTC)—Cont'd
Staff letter to Puerto Rico Treasury and Financial Affairs Committee objecting to bill permitting health-care providers to collectively negotiate fees (Jan. 30, 2008), **App. D118**
Staff letter to Rep. Patrick McHenry Concerning Proposed Bill Regulating Pharmacy Benefit Manager Contractual Relationships (Jul. 15, 2005), **App. D108**
Staff letter to Senator James L. Seward, New York Senate, concerning pharmacy-benefit-manager regulation (Mar. 31, 2009), **App. D123**
Staff letter to Tennessee senate concerning bill regulating optometry (Apr. 29, 2003), **App. D100**
Staff opinion letter to TriState Health Partners (Apr. 13, 2009), **App. D124**
State Action Doctrine, **App. E78**
Statement before Joint Committee on Health, West Virginia Legislature, **App. E76**
Statement of, second circuit order
Pharma Bro Martin Shkrelis lifetime ban, upholding, **App. B25**
Statement of chair Lina M. Khan joined by commissioners alvaro m. bedoya & rebecca kelly slaughter regarding the pharmacy benefit managers interim staff report (July 9, 2024), **App. G20**
Statement of commissioner Rebecca Kelly slaughter regarding ftc staff interim report
pharmacy benefit managers (August 1, 2024), **App. G21**
Statement of FTC Bureau of Competition Deputy Director Rahul Rao on Lawsuit Against PBMs and the Role of Drug Manufacturers in Distorting Competition in the U.S Drug

FEDERAL TRADE COMMISSION (FTC)—Cont'd
Distribution System (September 20, 2024), **App. G26**
Statement of Richard A. Feinstein, FTC Bureau of Competition, on the FTC's Closure of its Investigation of Consummated Hospital Merger in Temple, Texas (Dec. 23, 2009), **App. E55**
Statement of the Federal Trade Commission's Bureau of Competition on Guidelines for Merger Investigations (Dec. 11, 2002), **App. B3F**
State of Rhode Island v. Lifespan Corporation and Care New England Health System, statement, **App. E138**
Study on pharmacy benefit managers, chair remarks, **App. E139**
Supplemental Staff Submission to Indiana Health Department regarding
2025 Certificate of Public Advantage application of Union Health and Terre Haute Regional Hospital (March 17, 2025), **App. G33**
Telehealth services, FTC Advocacy letter to Alaska State Legislature concerning (Mar. 25, 2016), **App. D179**
Temporary restraining order
pursuant to Section 13(b) of the Federal Trade Commission Act, **App. G10**
Tennessee House of Representatives, letter concerning bill to regulate pain management services, **App. D142**
Tennessee Legislature, letter concerning repeal of state-action exemption legislation for Tennessee public hospitals, **App. D139**
Texas House of Representatives, letter concerning bill to permit health care collaboratives, **App. D138**

FEDERAL TRADE COMMISSION (FTC)—Cont'd
Texas State Board Examiners, Staff advocacy letter to Simone Salloum, concerning proposed rules (Oct. 14, 2014), **App. D161**
Texas State Senate, letter concerning regulation of advanced registered nurse practitioners, **App. D137**
Treatment of debt as consideration, **App. B16**
Under Section 7 of Clayton Act, **§ 8:18**
"Unfair Methods of Competition" under Section 5 of FTC Act, statement of enforcement principles regarding (Aug. 13, 2015), **App. G2**
Unfair Methods of Competition Under Section 5 of the FTC Act, Adoption of the Statement of Enforcement Policy, **App. E147**
Unfair trade practices, "Section 5: Principles of Navigation" (July 25, 2013), **App. E86**
United States Senate Committee on the Judiciary Subcommittee on Antitrust, **App. E146**
Use of prior approval provisions in merger orders, **App. B17**
U.S. Senators, letter concerning antitrust and accountable care organizations, **App. D134**
Vertically Integrated Pharmacy Specialty Generic Drugs
Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers (January 14, 2025), **App. G30**
Veterans Administration, advocacy letter, advanced practice registered nurses restrictions (July 25, 2016), **App. D183**
Virginia Certificate of Need Work Group, joint statement of FTC and Antitrust Division (Oct. 26, 2015), **App. D172**
"What's Past is Prologue: FTC's Competition and Consumer

FEDERAL TRADE COMMISSION (FTC)—Cont'd
Protection Priorities," text of remarks by Julie Brill, Commissioner, FTC, before the ABA Fall Forum (Nov. 6, 2014), **App. E102**
Workshop summary
Pharmaceutical mergers, analysis examination, **App. G12**

FEDERAL TRADE COMMISSION, PLAINTIFF, V. SURESCRIPTS, LLC
Stipulated order for, equitable relief and permanent injunction, **App. G15**

FEDERAL TRADE COMMISSION ACT
Generally, **§ 7:13**
Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E147**
Text of, excerpts, **App. A5**

FEES
FTC Staff letter to Puerto Rico Treasury and Financial Affairs Committee objecting to bill permitting health-care providers to collectively negotiate fees (Jan. 30, 2008), **App. D118**

FEINSTEIN, DEBORAH L.
"Antitrust Enforcement in Health Care: Proscription, Not Prescription," remarks by Deborah L. Feinstein, Director, Bureau of Competition, FTC, before the Fifth National Accountable Care Organization Summit (June 19, 2014), **App. E98**
"The Forward-Looking Nature of Merger Analysis," remarks by Deborah L. Feinstein, Director, Bureau of Competition, FTC (Feb. 6, 2014), **App. E96**

FINAL DECISION AND ORDER
Welsh, Carson, Anderson & Stowe, in matter of, **App. G37**

FINANCIAL RISK SHARING
Provider-controlled contracting networks, antitrust safety zones, **§ 20:5**

FIRMS
See also Business (this index)

FIRST LOOK, LLC
Advisory opinions (June 19, 1997), **App. D75**

FIRST PRIORITY HEALTH
Business review letter (Nov. 3, 1997), **App. C84**

FISCAL YEAR 2024
Hart-Scott-Rodino Annual Report, **App. D208**

FLORIDA STATE SENATE
Federal Trade Commission prepared statement concerning certificate of need laws (Apr. 2, 2008), **App. E46**

FOLLOW-ON BIOLOGICS
Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E54**

FOOD AND DRUG ADMINISTRATION (FDA)
Antitrust implications, listing a drug in Orange Book, **26:1**
FDA/FTC workshop
competitive marketplace for biosimilars, **App. D203**
opening remarks of Chairman Joseph Simons, **App. E130**
Statement, collaboration to advance competition in biologic marketplace, **App. F6**

FORMAN, ANDREW
Keynote speech, **App. E143**

FOUNDATION FOR THE ACCREDITATION OF HEMATOPOIETIC CELL THERAPY
Advisory opinions (Apr. 17, 1997), **App. D72**

FRIMET, GILBERT M.
Advisory opinion, **App. D8**

FTC
Generally. Federal Trade Commission (FTC) (this index)

FTC AGREEMENT CONSENT ORDER
Gateway Services, Inc. and Gateway US Holdings, Inc., **App. F8**

FTC AMICUS BRIEF
Re Bystolic Antitrust Litigation, **App. D206**

FTC CLARKE EDWARDS LETTER
Senator Brad Hutto, **App. D209**

FTC COMPLAINT
In the Matter of Centerbridge Seaport Acquisition Fund, L.P., **App. F12**

FTC EXECUTIVE SUMMARY, "POLICY PERSPECTIVES: COMPETITION AND THE REGULATION OF ADVANCED PRACTICE NURSES" (MAR. 2014)
Generally, **App. E95**

FTC HEALTHCARE NON-COMPETE
Warning Letter Template, **App. F11**

FTC LETTER
Pharmaceutical benefit managers regulation, letter to Virginia House of Delegates (Oct. 2, 2006), **App. D113**
Pharmacy benefit managers (''PBMs'') and ''covered entities,'' House Bill 1332 (''HB 1332'' or the ''Bill'') that would regulate the contractual relationships between, **App. D105**

FTC LETTER—Cont'd
Virginia House of Delegates concerning regulation of pharmaceutical benefit managers (Oct. 2, 2006), **App. D113**

FTC NON-COMPETE COMPLAINT
Gateway Services, Inc. & Gateway US Holdings, Inc., **App. F7**

FTC V. LOUISIANA CHILDRENS MEDICAL CENTER,
Petition, **App. G14**

FTC V. U.S. ANESTHESIA PARTNERS, INC.
Federal complaint for injunction, **App. G17**

FUNDAMENTAL CONCEPTS
Of Section 1, Sherman Act. Sherman Act (this index)

GALES REXALL DRUG
Business review letter, **App. C1**

GASTROENTEROLOGY ASSOCIATES, LTD
Business review letter (July 7, 1997), **App. C82**

GATEWAY PET MEMORIAL SERVICES
Andrew N. Ferguson & Melissa Holyoak Statement, **App. F9**

GATEWAY SERVICES, INC. & GATEWAY US HOLDINGS, INC.
FTC Agreement Consent Order, **App. F8**
FTC Non-Compete Complaint, **App. F7**

GAYNOR, MARTIN
''Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care,'' text of remarks before the 2014 American Antitrust Institute Annual Conference, **App. E100**

GENERIC DRUGS
''How Pay-for-Delay Settlements Make Consumers and the Federal Government Pay More for Much Needed Drugs,'' prepared statement before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives (Mar. 31, 2009), **App. E49**
Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E54**

GEORGE MASON SCHOOL OF LAW
''Brother, May I, The Challenge of Competitor Control over Market Entry'' remarks of Maureen K. Ohlhausen, Commissioner, before George Mason School of Law Global Antitrust Economics Conference (May 29, 2015), **App. E109**

GEORGETOWN GLOBAL ANTITRUST SYMPOSIUM
''The FTC's Role in Shaping Antitrust Doctrine: Recent Successes and Future Targets,'' Joshua D. Wright, Washington, D.C. (Sept. 24, 2013), **App. E89**

GEORGE WASHINGTON UNIVERSITY LAW SCHOOL
''Retrospectives at the FTC: Promoting an Antitrust Agenda,'' text of remarks of Edith Ramirez, Chairwoman, FTC, at the Merger Transactions Symposium (June 28, 2013), **App. E99**

GEORGIA GENERAL ASSEMBLY
U.S. Department of Justice Antitrust Division, ''Competition in healthcare and certificate of need'' (Feb. 23, 2007), **App. E39**

GEORGIA GENERAL ASSEMBLY —Cont'd

GEORGIA PREFERRED PODIATRIC MEDICAL NETWORK
Business review letter (Nov. 3, 1995), **App. C58**

GEORGIA STATE SENATE
FTC Advocacy letter to Hon. Valencia Seay concerning supervision of dental hygienists (Jan. 29, 2016), **App. D175**

GERMANY
''Protecting Consumer Welfare in the U.S. Health Care Sector,'' before the Mentor Group Forum for EU-US Legal-Economic Affairs, Berlin, Germany (Sept 13, 2013), **App. E87**

GI ASSOCIATES, P.C.
Business review letter (July 7, 1997), **App. C82**

GLOBAL ANTITRUST ECONOMICS CONFERENCE AND SYMPOSIUM
''Brother, May I, The Challenge of Competitor Control over Market Entry'' remarks of Maureen K. Ohlhausen, Commissioner, before George Mason School of Law Global Antitrust Economics Conference (May 29, 2015), **App. E109**
''The Horizontal Merger Guidelines Five Years Later'' text of remarks of Edith Ramirez before Georgetown University Law Center Ninth Symposium (Sept. 29, 2015), **App. E113**

GOVERNMENT ENFORCEMENT STATEMENTS
Antitrust laws, **§ 1:7**

GOVERNMENT JUDGMENTS
Effect of, in damage actions, **§ 11:14**

GREATER ROCHESTER INDEPENDENT PRACTICE ASSOCIATION
Advisory opinions (Sept. 17, 2007), **App. D116**

GROUP PURCHASING PROGRAMS
Analyzing, **§ 16:8**
''U.S. v. AzHAA: When Does a Group Purchasing Organization Become an Illegal Monopsonist,'' prepared remarks before AHLA annual meeting (June 26, 2007), **App. E41**

GUIDELINES
Federal government antitrust guidelines, **§ 1:8**

HAL WHITE ANTITRUST CONFERENCE
''Competition in Health Care Markets,'' text of remarks by Julie Brill, Commissioner, FTC, at 2014 Conference (June 9, 2014), **App. E97**

HANGER ORTHOPEDIC GROUP, INC.
Business review letter (Sept 15, 1995), **App. C55**

HARBOUR, PAMELA JONES
''A 'Check-Up' of Selected Health Care Activity at FTC,'' remarks before ABA antitrust law spring meeting (Mar. 30, 2005), **App. E32**

HART-SCOTT-RODINO ACT
Premerger Notification Office filing-fee information, **App. B3B**
Premerger Notification Office style sheet for filings, **App. B3A**

HART-SCOTT-RODINO ANNUAL REPORT
Fiscal Year 2024, **App. D208**
44th, FTC and Department of Justice, **App. D204**

HARVARD VANGUARD MEDICAL ASSOCIATES, INC.
Advisory opinions (Dec. 18, 2001), **App. D88**

HEALTH AND PERSONAL CARE DISTRIBUTION CONFERENCE, INC.
Business review letter, **App. C34**

"HEALTH CARE GUIDELINES AND ASSOCIATIONS, HOW ASSOCIATIONS CAN WORK WITH THE DEPARTMENT OF JUSTICE"
(Speech), **App. E2**

HEALTH CARE INFORMATION EXCHANGES
Federal Trade Commission staff advocacy letter to Sen. Chip Shields, Oregon State Legislature concerning antitrust immunity (May 18, 2015), **App. D166**

HEALTH CARE MANAGEMENT ASSOCIATES
Advisory opinion, **App. D3**
Business review letter, **App. C14**

HEALTH CARE QUALITY IMPROVEMENT ACT
Antitrust exemptions, **§ 9:12**
Practitioner credentialing and, **§ 9:12, § 13:8**
Text of, **App. A8**

HEALTHCARE SUMMIT
''Enforcement Strategies in the Health Care Industry,'' prepared remarks of J. Thomas Rosch before ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E48**

HEALTH CARE TECHNOLOGY
''Health Care Technology: Promoting Competition and Protecting Innovation,'' Maureen K. Ohlhausen, Commissioner of FTC, before Connecticut Bar Association Antitrust amp:

HEALTH CARE TECHNOLOGY —Cont'd
Trade Regulation and Consumer Law Sections (Feb. 26, 2014), **App. E94**

HEALTH COVERAGE, INSURANCE, AND FINANCIAL SERVICES
LD 97 supporting testimony
Division Director, Licensing & Certification at State of Maine, **App. G11**

HEALTH DEPARTMENT
Staff Submission to Indiana Health Department Regarding the Certificate of Public Advantage Application of Union Health and Terre Haute Regional Hospital (September 5, 2024), **App. G27**

HEALTH INFORMATION TECHNOLOGY
FTC Staff advocacy letter to Department of Health and Human Services concerning interoperability (Apr. 3, 2015), **App. D163**

HEALTH PLAN MARKET POWER
Generally, **§ 21:1**
All-products provisions and payer monopoly power, **§ 21:7**
Exclusions from providers from health plans or contracting networks, generally, **§ 21:8, § 21:9**
Exclusive contracting, **§ 21:9**
Low reimbursement and payer monopoly power, **§ 21:5**
McCarran-Ferguson Act's effects, generally, **§ 21:2**
Monopsony power. See Payer monopsony power, below
Most-favored-nations provisions and payer monopoly power, **§ 21:6**
Networks, provider exclusions from. See entries throughout this topic
Participation agreements between providers and payers, **§ 21:3**
Payer monopsony power generally, **§ 21:4 to 21:7**

HEALTH PLAN MARKET POWER —Cont'd
Payer monopsony power—Cont'd
all-products provisions and, **§ 21:7**
low reimbursement and, **§ 21:5**
most-favored-nations provisions and, **§ 21:6**
Provider exclusions from networks. See entries throughout this topic
Reimbursement and payer monopoly power, low reimbursement, **§ 21:5**
Selective and exclusive contracting, **§ 21:9**

HEALTH-PLAN MERGERS
Mergers, **§ 15:33**

HEALTH PLANNING
Market-allocation agreements and. Market-Allocation Agreements (this index)

HEALTH PLANNING ACT
Antitrust laws and, **§ 22:2**

HEMATOLOGY/ONCOLOGY CARE SPECIALISTS OF WESTERN PENNSYLVANIA, P.C.
Advisory opinions (Sept. 21, 1995), **App. D54**

HENRY COUNTY MEMORIAL HOSPITAL
Advisory opinions (Apr. 10, 1997), **App. D74**

HERITAGE ALLIANCE AND LACKAWANNA PHYSICIANS ORGANIZATION
Business review letter (Sept. 15, 1998), **App. C86**

HIGHLY INNOVATED INDUSTRIES
"Mergers that Increase Bargaining Leverage," Aviv Nevo, Deputy Assistant Attorney General for Economics, Antitrust Division, before Stanford Institute for Economic Policy Research and Cornerstone Research Confer-

HIGHLY INNOVATED INDUSTRIES—Cont'd
ence on Highly Innovated Industries (Jan. 22, 2014), **App. E93**

HISTORY
Of antitrust laws, **§ 1:3**
Of enforcement in health care sector, **§ 1:6**

HMO EXCLUSIVE CONTRACTS
Advisory opinion, **App. D24**

HOME CARE ALLIANCE, INC.
Business review letter (Oct. 4, 1996), **App. C73**

HOME CARE PROVIDERS
FTC staff letter to Hon. William J. Seitz, Ohio State Senator, concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D120**

HOME HEALTH INVESTIGATION
Vermont, U.S. Dept. of Justice statement on closing of Vermont home health investigation, **App. E35**

HOME HEALTH SERVICES ACT OF 2005
U.S. Dept. of Justice statement on closing of Vermont home health investigation, **App. E35**

HORIZONTAL AGREEMENTS
"A Stepwise Approach to Antitrust Review of Horizontal Agreements" (speech), **App. E15**
Under Section 1 of Sherman Act
generally, **§ 4:1, § 4:4**
agreements to exchange or disseminate information, **§ 4:3**
bid-rigging agreements, **§ 4:5**
concerted refusals to deal, **§ 4:7**
covenants not to compete, **§ 4:6**
health planning activities and, **§ 22:5**
horizontal market-allocation agreements, **§ 4:4**

HORIZONTAL AGREEMENTS —Cont'd
Under Section 1 of Sherman Act —Cont'd
horizontal price-fixing agreements, **§ 4:2**
mergers and joint ventures, **§ 4:8**
standard-setting programs, **§ 4:10**
unfair competition and dirty tricks, **§ 4:9**

HORIZONTAL MERGERS
Department of Justice and Federal Trade Commission guidelines, **§ 15:9, App. B1**
Department of Justice business review procedure, **App. B4**
FTC advisory opinions procedure, **App. B5**
FTC statement on (1982), **App. B2**
Guidelines, Department of Justice and FTC, **§ 15:9, App. B1**
1984 Department of Justice guidelines, **App. B6**
"The Horizontal Merger Guidelines Five Years Later" text of remarks of Edith Ramirez before Georgetown University Law Center Ninth Annual Global Antitrust Enforcement Symposium (Sept. 29, 2015), **App. E113**
Under Section 7 of Clayton Act
generally, **§ 8:5**
collusion, market characteristics and ease of, **§ 8:10**
concentration, **§ 8:6**
defenses, **§ 8:13**
efficiencies from merger, **§ 8:12**
entry into market, **§ 8:9**
financial viability, **§ 8:11**
other factors, **§ 8:7**
rebuttal evidence, generally, **§ 8:8 to 8:12**

HOSPICE NETWORK OF NEW JERSEY, INC.
Business review letter (April 24, 1996), **App. C67**

HOSPITAL CONSOLIDATION
Statement before Committee on the Judiciary Subcommittee on Competition Policy, Antitrust, and Consumer Rights, **App. E136**

HOSPITAL CORPORATION OF AMERICA
Business review letter, **App. C15**

HOSPITAL ORGANIZATION
Credentialing process and
generally, **§ 13:2**
see also Practitioner Credentialing (this index)

HOSPITALS
See more specific entries throughout this index

HOTEL EMPLOYEES AND RESTAURANT EMPLOYEES INTERNATIONAL UNION WELFARE FUND
Business review letter, **App. C41**

HOUSTON HEALTH CARE COALITION
Business review letter, **App. C39**

HUMAN RESOURCES
DOJ and FTC antitrust guidance (Oct. 2016), **App. G3**

HYATT IMLER OTT & BLOUNT, P.C.
Business review letter, **App. C28**

IDENTIFICATION
Competitor, mergers and, **§ 15:12**

ILLINOIS STATE REPRESENTATIVE
Letter from FTC concerning proposed regulation of retail health care facilities (May 29, 2008), **App. D121**

IMMUNITIES
Exemptions and Immunities (this index)

IMPLIED REPEAL
Of antitrust laws, **§ 9:5**

INDEPENDENT DRUG WHOLESALERS GROUP
Business review letter, **App. C23**

INDIANA HEALTH DEPARTMENT
Supplemental staff submission regarding 2025 Certificate of Public
Advantage application of Union Health and Terre Haute Regional Hospital (March 17, 2025), **App. G33**

INFORMATION
Under Section 1 of Sherman Act, **§ 4:3**

INJUNCTION
FTC v. U.S. Anesthesia Partners, Inc., federal complaint, **App. G17**

INJUNCTIVE RELIEF
In damage actions, **§ 11:15**

INJURY
Antitrust, as element of damage action, **§ 11:6**
In damage actions, **§ 11:3**
In private treble-damage litigation under Robinson-Patman Act, **§ 7:11**

IN PARI DELICTO DEFENSE
In damage actions, **§ 11:11**

IN-SCHOOL DENTISTRY
FTC staff letter to Hon. Timothy G. Burns, Louisiana House of Representatives, concerning in-school dentistry (May 1, 2009), **App. D125**

INSURANCE
Business of, antitrust exemption, **§ 9:10**

"INTEGRATED JOINT VENTURES"
(Speech), **App. E9**

INTENT
Purpose or. Purpose or Intent (this index)
Specific, to monopolize, under Section 2 of Sherman Act, **§ 6:14**

INTERLOCKING DIRECTORIES
Generally, **§ 7:1**

INTERNATIONAL CHIROPRACTORS ASSOCIATION
Business review letter, **App. C3**

INTERSTATE COMMERCE
Effect on substantial amount of, exclusive contracts and, **§ 14:7**
Mergers and, **§ 15:7**
Practitioner credentialing and, **§ 13:5**
Subject matter jurisdiction, **§ 2:2**

INTRACORP
Advisory opinion, **App. D26**

INVESTIGATIONS
Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E29**
Consummated hospital merger in Temple, Texas, statement of Richard A. Feinstein, Competition Director, FTC Bureau of Competition, on FTC's closure of investigation of (Dec. 23, 2009), **App. E55**
FTC enforcement, **§ 10:8**
Premerger, **§ 15:8**
Protocol for coordination in merger investigations between federal enforcement agencies and state attorneys general, **App. B3G**
Vermont, U.S. Dept. of Justice statement on closing of Vermont home health investigation, **App. E35**

INVESTMENT INTERESTS
Physician-Owned Facilities (this index)

ITASCA CLINIC AND GRAND RAPIDS MEDICAL ASSOCIATES
Business review letter (March 19, 1996), **App. C65**

JAZZ PHARMACEUTICALS V. AVADEL CNS PHARMACEUTICALS
FTC amicus brief, **App. D202**

JOINT VENTURES
Generally, **§ 16:1**
Analyzing agreements relating to operation of, **§ 16:5**
Analyzing formation of, **§ 16:4**
Analyzing particular
generally, **§ 16:7**
group purchasing programs, **§ 16:8**
joint venture among competitors to provide new services, expensive equipment, and specialized services, **§ 16:9**
joint ventures between hospitals and physicians, **§ 16:10**
Classifications of, **§ 16:3**
Collaboration Guidelines, overview of, **§ 16:6**
Definition of, **§ 16:2**
''Integrated Joint Ventures'' (speech), **App. E9**
Physician-owned facilities, **§ 18:3**
Practical factors and danger signals in, **§ 16:11**
Provider-Controlled Contracting Networks (this index)
Under Section 7 of Clayton Act, **§ 8:16**
Under Section 1 of Sherman Act, as horizontal agreements, **§ 4:8**

"JOINT VENTURES IN EVOLVING HEALTH CARE MARKETS"
(Speech), **App. E1**

JUDICIARY SUBCOMMITTEE ON ANTITRUST
United States Senate Committee, Competition Policy and Consumer RightsOversight of

JUDICIARY SUBCOMMITTEE ON ANTITRUST—Cont'd
the Enforcement of the Antitrust Laws, **App. E146**

JURISDICTION
Primary and exclusive, **§ 9:6**

JUSTICE DEPARTMENT (UNITED STATES DEPARTMENT OF JUSTICE; ANTITRUST DIVISION)
See also more specific entries throughout this index
Additional information, documentary material request, **App. B9**
Arbitration and case selection, guidance, **App. B11**
Business review procedure of
generally, **§ 10:6, App. B4**
see also Business review letter (this index)
Certificate-of-need laws and Alaska, joint statement of FTC and Antitrust Division (Apr. 7, 2017), **App. D189**
DOJ and FTC joint antitrust statement regarding COVID-19 (March 2020), **App. G4**
Enforcement by. Enforcement (this index)
FTC and DOJ FAQ, voluntary expedited review, statement of Antitrust Enforcement Policy Regarding ACOs, Medicare Shared Savings Program, **App. F5**
Guidelines on mergers
generally, **App. B1**
horizontal mergers, **§ 15:9, App. B6**
Health care Business review letter. Business review letter (this index)
Human resource professionals, DOJ and FTC antitrust guidance (Oct. 2016), **App. G3**
Joint DOJ/FTC letter to Alaska on CON laws (March 11, 2019), **App. F4**

JUSTICE DEPARTMENT (UNITED STATES DEPARTMENT OF JUSTICE; ANTITRUST DIVISION)—Cont'd
Joint DOJ/FTC letter to Tennessee on CON laws (March 7, 2019), **App. F3**
Joint FDA-FTC statement, collaboration to advance competition in the biologic marketplace (February 3, 2020), **App. F6**
Letter, Maryland, board certification of medical physicians (September 10, 2018), **App. F2**
Matters resolved without a case filed, **App. G9**
Merger Review Process Initiative, **App. B3C**
Mergers and, **§ 15:9, App. B1, App. B6**
''Mergers that Increase Bargaining Leverage,'' Aviv Nevo, Deputy Assistant Attorney General for Economics, Antitrust Division, before Stanford Institute for Economic Policy Research and Cornerstone Research Conference on Highly Innovated Industries (Jan. 22, 2014), **App. E93**
''Origin of the Species: The 100 Year Evolution of the Clayton Act,'' text of remarks of William J. Baer, Assistant Attorney General, Antitrust Division, before the ABA Clayton Act 100th Anniversary Symposium (Dec. 4, 2014), **App. E103**
Policy guide to merger remedies, **App. B7**
Second-request internal appeal procedure, **App. B3D**
Summary of business reviews, **App. C107**
Summary of health care cases (Since August 25, 1983) (2020), **App. G8**
Under Section 7 of Clayton Act, **§ 8:18**
Vermont, U.S. Dept. of Justice statement on closing of Vermont

JUSTICE DEPARTMENT (UNITED STATES DEPARTMENT OF JUSTICE; ANTITRUST DIVISION)—Cont'd
home health investigation, **App. E35**

KAISER FOUNDATION HEALTH PLAN
FTC staff advisory opinion to Kaiser Foundation Health Plan (Feb. 13, 2008), **App. D119**

KENTUCKY HOUSE OF REPRESENTATIVES
Denturists, FTC Advocacy letter concerning regulation (Mar. 25, 2016), **App. D180**

KHAN, LINA M.
Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E147**
Study on Pharmacy Benefit Managers, **App. E139**

KITSAP PHYSICIANS SERVICE
Advisory opinions
March 26, 1984, **App. D9**
May 22, 1984, **App. D11**

LABOR
Antitrust exemption, **§ 9:11**

LD 97
Supporting testimony
Division Director, Licensing & Certification at State of Maine, **App. G11**

LEGISLATIVE CHANGES
Antitrust laws, **§ 1:7**

LEGISLATIVE EXEMPTION
Physician collective bargaining, letter from FTC to Insurance Committee, Ohio House of Representatives, **App. D93**

LETTER
Letter from Office of Policy Planning Acting Director Clarke Edwards to Senator Juan Barnett Concerning Mississippi H.B. 1057 to Address the Practice of Advanced Practice Registered Nurses (January 25, 2026), **App.F15**
Letter to Azurity Pharmaceuticals, **App. G40**

LETTER TO DELEGATE PURKEY REGARDING VIRGINIA HOUSE BILLS 2518 AND 160 AND VIRGINIA SENATE BILL 272
Optometric care, **App. D106**

LEVERAGING
Under Section 2 of Sherman Act
as anticompetitive conduct, **§ 6:9**
diversification and, **§ 17:11**

LEXECON HEALTH SERVICE
Business review letter, **App. C17**

LICENSURE
"Competition and Potential Costs and Benefits of Professional Licensure," prepared Statement of Andrew Gavil, Director, Office of Policy Planning, before Committee of Small Business, U.S. House of Representatives (Jul. 16, 2014), **App. E104**
"Death by a Thousand Haircuts: Economic Liberty and Occupational Licensure Reform," **App. E121**
Eliminating certain occupational licensing requirements, FTC staff advocacy letter (Mar. 15, 2017), **App. D188**
"License to Compete: Occupational Licensing and the State Action Doctrine," prepared Statement of FTC before the United States Senate Committee on the Judiciary (Feb. 2, 2016), **App. E115**
Occupational Licensing in Health Care: Sorting the Wheat from the Chaff (June 19, 2020), **App. E132**

LINEN SYSTEMS FOR HEALTHCARE, LLC
Business review letter (Aug. 8, 2006), **App. C95**

LITIGATION
Discovery in staff-privilege antitrust, practitioner credentialing and, **§ 13:20**
FTC enforcement
generally, **§ 10:9**
see also Enforcement (this index)

LOBBYING
Physician-owned facilities, lobbying by hospitals against, **§ 18:3**

LOCAL GOVERNMENT ANTITRUST ACT
Antitrust exemptions, **§ 9:9**
Practitioner credentialing and, **§ 13:7**
Text of, **App. A6**

LOUISIANA HEALTH CARE ASSOCIATION
Advisory opinion, **App. D2**

LOUISIANA HOUSE OF REPRESENTATIVES
Letter from FTC to Hon. Timothy G. Burns concerning in-school dentistry (May 1, 2009), **App. D125**

LOUISIANA STATE BOARD OF DENTISTRY
FTC Staff comments to Louisiana State Board of Dentistry regarding proposed modifications to Louisiana Rules regarding the practice of portable and mobile dentistry (Dec. 9, 2009), **App. D126**

LOW REIMBURSEMENT
Health plan market power, payer monopoly power and low reimbursement, **§ 21:5**

MANAGED CARE
Antitrust laws, **§ 1:7**

MARIN GENERAL HOSPITAL
Business review letter (Feb. 11, 1997), **App. C77**

MARKET-ALLOCATION AGREEMENTS
Generally, **§ 22:1**
Agency opposition to CON, **§ 22:3**
Antitrust ramifications of certificate-of-need proceedings, **§ 22:4**
Certificate-of-need
agency opposition, **§ 22:3**
antitrust ramifications of proceedings, **§ 22:4**
pros and cons, **§ 22:3**
Conclusion, **§ 22:6**
Health Planning Act and antitrust laws, **§ 22:2**
Health-planning activities and horizontal, **§ 22:5**
Under Section 1 of Sherman Act
horizontal agreements, **§ 4:4**
vertical agreements, **§ 5:3**

MARKET POWER
Health plans, generally. Health Plan Market Power (this index)
In market for tying product, exclusive contracts and, **§ 14:6**
Provider-Controlled Contracting Networks (this index)

MARKET REALITIES REPORTS
Current, FTC statement for, **App. D207**

MARKET REVIEW PROCESS
Massachusetts Chapter 343, An Act Enhancing
Key Provisions in effect 4-8-25, **App. G36**

MARKETS
Competitive effects in other, mergers and
see also Relevant Market (this index)
Summary report, FDA/FTC workshop on a competitive marketplace for biosimilars, **App. D203**

MARKET SHARE
Calculation, mergers and, **§ 15:12**

MARYLAND HEALTH CARE COALITION
Business review letter, **App. C11**

MARYLAND MEDICAL EYE ASSOCIATES
Advisory opinion, **App. D25**

MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH
Clinic advertising, FTC staff letter concerning (Sept. 27, 2007), **App. D117**

MASSACHUSETTS HOUSE OF REPRESENTATIVES
Nurse practitioners and nurse anesthetists, FTC letter concerning removal of supervision requirement (Jan. 17, 2014), **App. D157**
Optometrists treating glaucoma patients, FTC and DOJ Advocacy letter concerning (Feb. 18, 2016), **App. D177**

MAYO MEDICAL LABORATORIES
Advisory opinions (July 17, 1996), **App. D61**

MCCARRAN-FERGUSON ACT
Health plan market power. Health Plan Market Power (this index)
Text of, **App. A7**

MCSWEENEY, TERRELL
''Reflections on an Active Year in Merger Enforcement,'' keynote remarks of Commissioner McSweeney (Feb. 5, 2016), **App. E116**

MEDICAL GROUP MANAGEMENT ASSOCIATION
Advisory opinion, **App. D101**

MEDICAL SCHOOL COLLABORATION AGREEMENTS
FTC Staff Advocacy letter to Alabama State Senate concerning

MEDICAL SCHOOL COLLABORATION AGREEMENTS—Cont'd
antitrust exemption for public university medical school agreements (May. 2, 2016), **App. D181**

MEDICAL SOCIETY OF THE COUNTY OF ERIE
Advisory opinion, **App. D6**

MEDICARE PRESCRIPTION DRUG, IMPROVEMENT, AND MODERNIZATION ACT
Physician-owned facilities, **§ 18:2**

MEDICARE PRESCRIPTION DRUG BENEFIT PROGRAM
FTC Staff Advocacy Letter to Centers for Medicare and Medicaid Services concerning any-willing-provider changes (Mar. 7, 2014), **App. D159**

MEDICARE SHARED SAVINGS PROGRAM
Provider-controlled contracting networks, **§ 20:15**

MEDSOUTH, INC.
Advisory opinion (Feb. 19, 2002), **App. D92**
FTC staff follow-up letter (June 18, 2007) to 2002 staff advisory opinion, **App. D115**

MEMBERSHIP RESTRICTIONS
Ethical issue in, **§ 24:8**

MENTOR GROUP FORUM FOR EU-US LEGAL-ECONOMIC AFFAIRS
''Protecting Consumer Welfare in the U.S. Health Care Sector,'' Berlin, Germany (Sept 13, 2013), **App. E87**

MERGER GUIDELINES
DOJ and FTC 2023, **App. B20**

MERGERS
Generally, **§ 15:1, App. B et seq.**
Affordable Care Act, **§ 15:22**

MERGERS—Cont'd
Analyzing hospital
generally, **§ 15:9**
Affordable Care Act, **§ 15:22**
competitor identification and market share calculation, **§ 15:12**
coordinating effects, **§ 15:15**
failing company defense, **§ 15:20**
nonprofit status, **§ 15:28**
order, special report, physician group and healthcare facility mergers, **App. B10**
party and consultant statements and documents about purpose and effect, **§ 15:26**
public and private commitments restraining exercise market power, **§ 15:27**
purchasers, below
rebutting the prima facie case, below
relevant geographic market, **§ 15:11**
relevant product market, **§ 15:10**
Anthem, Inc.'s acquisition of WellPoint Health Networks, Inc., Antitrust Division statement on closing of investigation of (March 9, 2004), **App. E30**
As anticompetitive conduct under Section 2 of Sherman Act, **§ 6:11**
Aviv Nevo, Deputy Assistant Attorney General for Economics, Antitrust Division, "Mergers that Increase Bargaining Leverage," Conference on Highly Innovated Industries (Jan. 22, 2014), **App. E93**
Blue Cross of Michigan and Physicians Health Plan of Mid-Michigan (Mar. 8, 2010), **App. E56**
Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E29**
Clayton Act Section 7A, premerger notification form and instructions under amended, **App. B3**

MERGERS—Cont'd
Competitors, complaints and opinions, **§ 15:25**
Consent order provisions, FTC frequently asked questions, **§ 15:36**
Cross-market, **§ 15:29**
Deborah L. Feinstein, Director, Bureau of Competition, FTC, "The Forward-Looking Nature of Merger Analysis," text of remarks (Feb. 6, 2014), **App. E96**
Defenses, failing company, **§ 15:20**
Department of Justice business review procedure, **App. B4**
Exemption of state-action, preliminary issues, **§ 15:6**
FTC
advisory opinions procedure, **App. B5**
Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E29**
deborah L. Feinstein, Director, Bureau of Competition, FTC, "The Forward-Looking Nature of Merger Analysis," text of remarks (Feb. 6, 2014), **App. E96**
frequently asked questions, merger consent order provisions, **§ 15:36**
guidelines on, Department of Justice and FTC, **§ 15:9**
"Retrospectives at the FTC: Promoting an Antitrust Agenda," text of remarks of Edith Ramirez before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E99**
staff letter to Louisiana attorney general concerning Tenet Healthcare Corporation's proposed acquisition of Slidell Memorial Hospital (Apr.

MERGERS—Cont'd
FTC—Cont'd
1, 2003), **App. D99**
statement in closing investigation of Caremark Rx/AdvancePCS merger (Feb. 11, 2004), **App. E29**
Statement of Richard A. Feinstein, FTC Bureau of Competition Director on the FTC's Closure of its Investigation of Consummated hospital merger in Temple, Texas (Dec. 23, 2009), **App. E55**
Guidelines on, Department of Justice and FTC, **§ 15:9, App. B1**
Health-plan mergers, **§ 15:33**
Horizontal Mergers (this index)
Hospital acquisition of physician practices, **§ 15:32**
Investigations
FTC statement in closing investigation of Caremark Rx/AdvancePCS merger (Feb. 11, 2004), **App. E29**
Statement of Richard A. Feinstein, FTC Bureau of Competition Director on the FTC's Closure of its Investigation of Consummated hospital merger in Temple, Texas (Dec. 23, 2009), **App. E55**
Jeffrey Schmidt, Director, Bureau of Competition, prepared slides before ABA Section of Antitrust Law 2007 Fall Forum concerning "Critical Loss Analysis: A Merger Lawyer's View" (Nov. 16, 2007), **App. E44**
"Litigating Merger Challenges: Lessons Learned," prepared remarks by J. Thomas Rosch before Bates White Fifth Annual Antitrust Conference (June 2, 2008), **App. E47**
1984 Justice Department guidelines on, **App. B6**
Other hospital health-care sector
generally, **§ 15:31**
health-plan mergers, **§ 15:33**

MERGERS—Cont'd
Other hospital health-care sector —Cont'd
hospital acquisition of physician practices, **§ 15:32**
other industries, **§ 15:34**
physician practices, **§ 15:32**
Physician practices, **§ 15:32**
Planning for a hospital, **§ 15:30**
Preliminary issues
generally, **§ 15:2**
economic effects of mergers, **§ 15:2**
interstate commerce, **§ 15:7**
premerger notification, investigation, and preliminary relief, **§ 15:8**
relevant federal antitrust statutes, **§ 15:3**
Section 7 and acquisitions by nonprofit entities, **§ 15:5**
state-action exemption, **§ 15:6**
virtual mergers and single entity status, **§ 15:4**
Protocol for coordination in merger investigations between federal enforcement agencies and state attorneys general, **App. B3G**
Purchasers
complaints, **§ 15:24**
opinions of, **§ 15:24**
size and sophistication of, **§ 15:23**
Rebutting the prima facie case
generally, **§ 15:16**
efficiencies, **§ 15:18**
"flailing firm," **§ 15:19**
low entry barriers, **§ 15:17**
weakened competitor, **§ 15:19**
"Reflections on an Active Year in Merger Enforcement," keynote remarks of Commissioner Terrell McSweeney at Antitrust Law Leaders Forum (Feb. 5, 2016), **App. E116**
Requests for additional information, FTC appeal procedure, **App. B8**
"Retrospectives at the FTC: Promoting an Antitrust Agenda," text of remarks of Edith Ramirez before

MERGERS—Cont'd
the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E99**
Section 7. Clayton Act (this index)
Statement of the Federal Trade Commission's Bureau of Competition on Guidelines for Merger Investigations (Dec. 11, 2002), **App. B3F**
State notification laws, **§ 15:35**
Under Section 7 of Clayton Act
and acquisitions by nonprofit entities, **§ 15:5**
conglomerate mergers and, **§ 8:15**
premerger notification requirements, **§ 8:17**
vertical mergers, **§ 8:14**
Under Section 1 of Sherman Act: horizontal agreements, **§ 4:8**
Unilateral effects
generally, **§ 15:14**
potential harms, coordinated effects, **§ 15:13**
United Health Group's acquisition of Oxford Health Plans, Antitrust Division background of closing investigation of (Jul. 20, 2004), **App. E31**
Vertical, **§ 15:29**
Virtual mergers and single entity status, **§ 15:4**
Voluntary self-disclosures
New Safe Harbor Policy, Deputy Attorney General Lisa O. Monaco, **App. B23**

MESA COUNTY PHYSICIAN INDEPENDENT PRACTICE ASSOCIATION
Federal Trade Commission Bureau of Competition staff advisory opinion regarding collective agreement, **App. D76A**

MESSENGER ARRANGEMENTS
Provider-controlled contracting networks, **§ 20:14**

MICHIGAN
Merger proposed, Blue Cross of Michigan and Physicians Health Plan of Mid-Michigan (Mar. 8, 2010), **App. E56**

MICHIGAN CERTIFICATE OF NEED COMMISSION
Letter from Joseph Miller, Assistant Chief, Antitrust Division, to Sen. Michael D. Bishop, Michigan Senate Majority Leader, concerning proposed standards (June 6, 2008), **App. C98**

MIDWEST BEHAVIORAL HEALTH LLC
Business review letter (Feb. 4, 2000), **App. C90**

MINNESOTA HOUSE OF REPRESENTATIVES
Letter from FTC concerning rural health care cooperative joint negotiations (Mar 18, 2009), **App. D122**

MOBILE AND PORTABLE DENTISTRY
FTC Staff comments to Louisiana State Board of Dentistry regarding proposed modifications to Louisiana Rules regarding the practice of portable and mobile dentistry (Dec. 9, 2009), **App. D126**

MOBILE HEALTH RESOURCES, LLC
Advisory opinions (Jan. 23, 1997), **App. D67**

MONOPOLIZATION
Generally, **§ 6:1**
Anticompetitive conduct
generally, **§ 6:4**
denial of access to essential facility, **§ 6:8**
leveraging, **§ 6:9**
mergers, **§ 6:11**
monopoly pricing, **§ 6:5**
other predatory or unreasonably exclusionary conduct, **§ 6:12**

MONOPOLIZATION—Cont'd
Anticompetitive conduct—Cont'd
predatory pricing, **§ 6:12**
refusals to deal, **§ 6:7**
vertical integration, **§ 6:10**
Attempted Monopolization (this index)
Conspiracy to monopolize, **§ 6:16**
Health Plan Market Power (this index)
Monopoly power, **§ 6:3**
Practitioner credentialing, analysis under Section 2 of Sherman Act, **§ 13:18**
Shared monopoly, **§ 6:17**
''U.S. v. AzHAA: When Does a Group Purchasing Organization Become an Illegal Monopsonist,'' prepared remarks before AHLA annual meeting (June 26, 2007), **App. E41**

MONOPSONY AND THE MEANING OF CONSUMER WELFARE
2006 Milton Handler Annual Antitrust Review, closer look at Weyerhaeuser (Dec. 7, 2006), **App. E38**

MONTANA DEACONESS MEDICAL CENTER
Advisory opinions (June 28, 1996), **App. D63**

MORROS & ASSOCIATES
Business review letter, **App. C6**

MOST-FAVORED-NATIONS PROVISIONS
Health plan market power, payer monopoly power and most-favored-nations provisions, **§ 21:6**

"NAKED" PRICE-FIXING AGREEMENTS
Generally, **§ 19:3**

NATIONAL CAPITAL SOCIETY OF PLASTIC AND RECONSTRUCTIVE SURGEONS
Advisory opinions (Apr. 23, 1991), **App. D30**

NATIONAL CARDIOVASCULAR NETWORK, INC.
Business review letter, **App. C32**

NEKRITZ, ELAINE
FTC letter to Illinois State Representative Nekritz concerning proposed regulation of retail health care facilities (May. 29, 2008), **App. D121**

NETWORKS
Anthem, Inc.'s acquisition of WellPoint Health Networks, Inc., Antitrust Division statement on closing of investigation of (March 9, 2004), **App. E30**
''Antitrust Analysis of Hospital Networks and Shared Services Arrangements'' (speech), **App. E12**
''Current Issues in Health Care Antitrust: Boycotts, Mergers, and Provider Networks'' (speech), **App. E8**
Dermatologists, Business review letter to Dr. Oswald L. Mikell regarding proposed network of, **App. C56**
Georgia Preferred Podiatric Medical Network, Business review letter (Nov. 3, 1995), **App. C58**
Health plan market power and exclusions from networks. Provider-Controlled Contracting Networks (this index)
Hospice Network of New Jersey, Inc., Business review letter (April 24, 1996), **App. C67**
National Cardiovascular Network, Inc., business review letter, **App. C32**
Oakland Physician Network, advisory opinions, **App. D48**

NETWORKS—Cont'd
Ohio Ambulance Network, Inc., advisory opinions (Jan. 23, 1997), **App. D66**
Oklahoma Physicians Network-IPA, Inc., Business review letter (Jan. 17, 1996), **App. C61**
Orange Pharmacy Equitable Network, advisory opinions (May 19, 1999), **App. D84**
Pharmaceutical Care Network, business review letter, **App. C18**
Phoenix Medical Network, Inc., advisory opinions (May 19, 1998), **App. D80**
Preferred Laboratory Access Network, Business review letter (Dec. 7, 1995), **App. C60**
Preferred Podiatric Network Inc., business review letter, **App. C45**
Price-Fixing Agreements (this index)
Provider-Controlled Contracting Networks (this index)
RWHC Network, Inc., Business review letter (Nov. 12, 1996), **App. C76**
Southern Arizona Therapy Network, Inc., advisory opinions (Dec. 7, 1995), **App. D58**

NEVO, AVIV
''Mergers that Increase Bargaining Leverage,'' before Stanford Institute for Economic Policy Research and Cornerstone Research Conference on Highly Innovated Industries (Jan. 22, 2014), **App. E93**

NEW HEALTH CARE INDUSTRY CONFERENCE
Integration, Consolidation, Competition in the Wake of the Affordable Care Act, text of remarks of Bill Baer, Assistant Attorney General, before the New Health Care Industry Conference (Nov. 15, 2015), **App. E114**

NEW JERSEY GENERAL ASSEMBLY
Pharmacy benefit managers, letter from Federal Trade Commission Bureau of Competition and Bureau of Economics concerning regulation (Apr. 17, 2007), **App. D114**

NEW JERSEY HOSPITAL ASSOCIATION
Business review letter, **App. C38**

NEW JERSEY PHARMACISTS ASSOCIATION
Advisory opinions (Aug. 12, 1997), **App. D76**

NEW SAFE HARBOR POLICY
Voluntary self-disclosures, Deputy Attorney General Lisa O. Monaco, **App. B23**

NEW YORK DEPARTMENT OF PUBLIC HEALTH
Certificates of Public Advantage, FTC staff advocacy letter concerning (Apr. 22, 2015), **App. D165**

NEW YORK SENATE
Letter from FTC concerning pharmacy-benefit-manager regulation (Mar 31, 2009), **App. D123**

NOERR-PENNINGTON DOCTRINE
Physician-owned facilities, **§ 18:3**

NON-COMPETE AGREEMENTS
Employee, ethical restraints, **18:4**

NONPROFIT ENTITIES
Section 7 of Clayton Act and acquisitions by, **§ 15:5**

NONPROFIT HEALTH CARE PROVIDERS
Ramifications of preferential pricing of
generally, **§ 23:4**
see also Resales of Preferentially Priced Commodities (this index)

NONPROFIT HEALTH CARE PROVIDERS—Cont'd
Ramifications of preferential pricing of—Cont'd
Federal Trade Commission advisory opinions, **§ 23:5**

NON-PROFIT INSTITUTIONS ACT
Federal Trade Commission (FTC), opinion concerning, **App. D150, App. D151**
FTC Staff Advisory Opinions
resales of preferentially priced commodities, **§ 23:5**
to Kaiser Foundation Health Plan, advisory opinion on purchase of discounted pharmaceuticals under Nonprofit Institutions Act exemption (Feb. 13, 2008), **App. D119**
to Quest Analytics Group concerning Non-Profit Institutions Act (Mar. 7, 2014), **App. D160**
Overview of, **§ 23:3**
Resales of Preferentially Priced Commodities (this index)
Text of, **App. A4**

NONPROFIT STATUS
Mergers and, **§ 15:28**

NORTH CAROLINA CHIROPRACTIC ASSOCIATION
Advisory opinion, **App. D5**

NORTH CAROLINA DENTAL DECISION
"Reflections on Supreme Court's North Carolina Dental Decision and the FTC's Campaign to Rein in State Action Immunity," Maureen K. Ohlhausen, Commissioner (Mar 31, 2015), **App. E106**

NORTH CAROLINA SENATE BILL 743
Give state action defense to UNC healths collaborative activities, FTC staff comment, **App. D205**

NORTH MISSISSIPPI HEALTH SERVICES
Advisory opinions
(Oct. 3, 1996), **App. D69**
(Jan. 7, 1998), **App. D79**
Business review letter, **App. C22**
FTC staff advisory opinion to (Aug. 16, 2005), **App. D109**

NORTH OTTAWA COMMUNITY HOSPITAL
Advisory opinions (Oct. 22, 1996), **App. D71**

NORTH TEXAS CHAPTER, AMERICAN COLLEGE OF SURGEONS
Advisory opinion, **App. D18**

NOTIFICATION
Premerger
merger and, **§ 15:8**
requirements under Section 7 of Clayton Act, **§ 8:17**
Section 7A of Clayton Act, premerger notification form and instructions under amended, **App. B3**
statement of Commissioner Christine S. Wilson in the matter of HSR Premerger Notification, **App. E144**
State merger notification laws, **§ 15:35**
Washington AG guidance on healthcare transactions notification requirement, **App. B14**

NOVANT HEALTH, INC. AND COMMUNITY HEALTH SYSTEMS, INC.
Administrative complaint, **App. G18**

NSM PURCHASING ASSOCIATION
Business review letter (Jan. 13, 1999), **App. C88**

NURSES AND NURSING
Advanced Practice Nursing (this index)

OHIO AMBULANCE NETWORK, INC.
Advisory opinions (Jan. 23, 1997), **App. D66**

OHIO EXECUTIVE ORDER 2007-23S
FTC staff letter to Hon. William J. Seitz, Ohio State Senator, concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D120**

OHIO HOSPITAL PURCHASING CONSORTIUM
Business review letter, **App. C13**

OHLHAUSEN, MAUREEN K.
''An Ounce of Antitrust Prevention is Worth a Pound of Consumer Welfare: The Importance of Competition Advocacy and Premerger Notification,'' before Eleventh Annual Competition Day, Santiago, Chile (Nov. 5, 2013), **App. E91**
''Brother, May I, The Challenge of Competitor Control over Market Entry'' remarks before George Mason School of Law Global Antitrust Economics Conference (May 29, 2015), **App. E109**
''Protecting Consumer Welfare in the U.S. Health Care Sector,'' before the Mentor Group Forum for EU-US Legal-Economic Affairs, Berlin, Germany (Sept 13, 2013), **App. E87**
''Reflections on Supreme Court's North Carolina Dental Decision and the FTC's Campaign to Rein in State Action Immunity'' (Mar 31, 2015), **App. E106**
''Section 5: Principles of Navigation,'' before U.S. Chamber of Commerce, Washington, DC (July 25, 2013), **App. E86**
''When Regulation Protects Privilege Instead of People: Government Restraints of Trade-A Competition Enforcer's Perspective,'' text of remarks before The

OHLHAUSEN, MAUREEN K. —Cont'd
Antitrust Enforcement Symposium 2015 of Journal of Antitrust Enforcement (June 27, 2015), **App. E111**

OKLAHOMA PHYSICIANS NETWORK-IPA, INC.
Business review letter (Jan. 17, 1996), **App. C61**

OLYMPUS AMERICA, INC.
Business review letter (Aug. 29, 2001), **App. C92**

OPTOMETRY AND OPTOMETRIC CARE
FTC and DOJ Advocacy letter to Massachusetts House of Representatives concerning permitting optometrists to treat glaucoma patients (Feb. 18, 2016), **App. D177**
FTC and DOJ joint comments to Puerto Rico House of Representatives (May 18, 2016), **App. D182**
FTC staff letter to Tennessee senate concerning bill regulating optometry (Apr. 29, 2003), **App. D100**
Letter to Delegate Purkey Regarding Virginia House Bills 2518 and 160 and Virginia Senate Bill 272, **App. D106**

ORAL SURGEONS
Dentists and Oral Surgeons (this index)

ORANGE BOOK
FDA listing, **26:1**

ORANGE LOS ANGELES MEDICAL GROUP, INC.
Business review letter (March 8, 1996), **App. C64**

ORANGE PHARMACY EQUITABLE NETWORK
Advisory opinions (May 19, 1999), **App. D84**

ORGANIZATION
And authority, FTC, enforcement, **§ 10:7**
Antitrust Division, enforcement, **§ 10:2**

ORTHOPAEDIC ASSOCIATES OF MOBILE, P.A.
Business review letter (Apr. 16, 1997), **App. C79**

OVERSIGHT OF THE ENFORCEMENT OF THE ANTITRUST LAWS
Prepared statement of FTC, United States Senate Committee on the Judiciary Subcommittee on Antitrust, **App. E146**

OXFORD HEALTH PLANS
Antitrust Division background of closing investigation of acquisition of Oxford Health Plans (Jul. 20, 2004), **App. E31**

PACIFIC INTERNATIONAL HEALTH
Advisory opinion, **App. D23**

PAN AMERICAN MANAGEMENT ASSOCIATES
Advisory opinion, **App. D27**

PARTIAL INTEGRATION OF BUSINESS FUNCTIONS
Joint Ventures (this index)

PARTICIPATION AGREEMENTS
Health plan market power, participation agreements between providers and payers, **§ 21:3**

PARTICIPATION PERCENTAGES
Provider-controlled contracting networks, physician network joint ventures (Statement 8), **§ 20:6**

PARTIES LIABLE
In damage actions, **§ 11:13**

PASSAIC COUNTY MEDICAL SOCIETY
Advisory opinion, **App. D19**

PATENTS
''Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry; Why Consumers and the Federal Government are Paying Too Much for Prescription Drugs,'' prepared statement of FTC before Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate (June 3, 2009)—Richard A. Feinstein, Director, Bureau of Competition, **App. E50**
''Exclusion Payments to Settle Pharmaceutical Patent Cases: They're B-a-c-k!,'' prepared remarks before second annual in-house counsel's forum on pharmaceutical antitrust (Apr. 24, 2006), **App. E36**
''FTC v. Actavis and the Future of Reverse Payment Cases,'' remarks of Joshua D. Wright, Commissioner, FTC, before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E90**
''How Pay-for-Delay Settlements Make Consumers and the Federal Government Pay More for Much Needed Drugs,'' prepared statement before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives (Mar. 31, 2009), **App. E49**

PAYER MONOPOLY POWER
Health Plan Market Power (this index)

PAYER-PROVIDER RELATIONSHIP
Provider-Payer Relationship (this index)

PAY-FOR-DELAY SETTLEMENTS
Exclusion Payment Settlements (this index)

PBM RELATED ADVOCACY
FTC statement for, **App. D207**

PEER REVIEW
Practitioner credentialing based on. Practitioner Credentialing (this index)

PEER REVIEW ORGANIZATIONS OF OHIO FOUNDATION
Advisory opinion, **App. D10**

PERMANENT INJUNCTION
In Federal Trade Commission, plaintiff, v. Surescripts, LLC stipulated order, **App. G15**

PETITION
FTC v. Louisiana Childrens Medical Center, **App. G14**

PHARMACEUTICAL CARE NETWORK
Business review letter, **App. C18**

PHARMACEUTICAL INDUSTRY
''Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry; Why Consumers and the Federal Government are Paying Too Much for Prescription Drugs,'' prepared statement of FTC before Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate (June 3, 2009)—Richard A. Feinstein, Director, Bureau of Competition, **App. E50**
''Antitrust Analysis of Reverse Payments After Actavis: Three Questions and Proposed Answers,'' text of remarks of Joshua D. Wright, Commissioner, FTC, before the ABA Master Course VII (Oct. 10, 2014), **App. E101**
''Exclusion Payments to Settle Pharmaceutical Patent Cases: They're B-a-c-k!,'' prepared remarks before second annual in-house counsel's forum on pharmaceutical antitrust (Apr. 24, 2006), **App. E36**
Federal Trade Commission Bureau of Competition and Bureau of Economics letter to New Jersey

PHARMACEUTICAL INDUSTRY—Cont'd
General Assembly concerning regulation of pharmacy benefit managers (Apr. 17, 2007), **App. D114**
Federal Trade Commission Office of Policy Planning, letter to Virginia House of Delegates concerning pharmacy-benefit managers (PBM) regulation (Oct. 2, 2006), **App. D113**
Follow-on biologics, Pay-for-Delay Settlements, and Authorized Generics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E54**
FTC amicus brief, Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals, **App. D202**
FTC staff advisory opinion to Kaiser Foundation Health Plan on purchase of discounted pharmaceuticals under Nonprofit Institutions Act exemption (Feb. 13, 2008), **App. D119**
''FTC v. Actavis and the Future of Reverse Payment Cases,'' remarks of Joshua D. Wright, Commissioner, FTC, before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E90**
House Bill 971 (Community Pharmacy Fairness Act of 2007), Prepared Statement of FTC Before U.S. House of Representatives Judicial Committee (Oct. 18, 2007)—David Wales, Bureau of Competition, **App. E43**
House Bill 1332 (''HB 1332'' or the ''Bill'') that would regulate the contractual relationships between pharmacy-benefit managers (''PBMs'') and ''covered entities,'' **App. D105**

PHARMACEUTICAL INDUSTRY —Cont'd
Keynote remarks of Commissioner Rebecca Kelly Slaughter, FTC/DOJ Pharmaceutical task force workshop, **App. E145**
Letter from FTC to New York Senator concerning pharmacy-benefit manager regulation (Mar 31, 2009), **App. D123**
Letter from Markus H. Meier, Crouse Health Hospital, sale of discount pharmaceuticals to employees and retirees, **App. D195**
Overview of FTC actions in pharmaceutical products and distribution (June 2026), **App. G6**
Patent settlements and Supreme Court, FTC prepared remarks, **App. E77**
Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E54**
''Pay-for-Delay Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers' Wallets, and Help Pay for Health Care Reform (The § 35 Billion Solution)'' prepared remarks of Jon Leibowitz (June 23, 2009), **App. E52**
Post-patent pharmaceutical markets, issues in, **App. E122**
Prepared Statement of FTC and Pharmaceutical Industry before Committee of Judiciary, US Senate (June 17, 2003)—Timothy J. Muris, Chairman, FTC, **App. E26**
Prepared Statement of FTC before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives (Mar. 31, 2009)—J. Thomas Rosch, Commissioner, FTC, **App. E49**
Staff advisory opinion letter, Markus Meier to Doylestown Health, discounted pharmaceuticals and devices, Non-Profit Institutions Act, **App. D199**
Staff letter to Rep. Patrick McHenry concerning proposed bill regulating pharmacy benefit manager contractual relationships (Jul. 15, 2005), **App. D108**
Statement of Timothy J. Muris, Chairman, FTC before the Committee on Energy and Commerce, **App. E22**
Study on pharmacy benefit managers, **App. E139**

PHARMACEUTICAL MANUFACTURERS ASSOCIATION
Business review letter, **App. C33**

PHARMACEUTICAL MERGERS
FTC-DOJ workshop summary, **App. G12**

PHARMACEUTICAL PATENT DISPUTES
Settlement of disputes, antitrust issues (speech by Thomas B. Leary)
(Part I), **App. E18**
(Part II), **App. E19**

PHARMACEUTICAL TASK FORCE WORKSHOP, FTC/DOJ
Keynote remarks of Commissioner Rebecca Kelly Slaughter, **App. E145**

PHOENIX MEDICAL NETWORK, INC.
Advisory opinions (May 19, 1998), **App. D80**

PHYSICIAN-OWNED FACILITIES
Generally, **§ 18:1 et seq.**

PHYSICIAN-OWNED FACILITIES —Cont'd
Actions to combat competition from medical staff members, **§ 18:3**
Adverse selection, **§ 18:2**
Ambulatory surgery centers (ASCs), **§ 18:2 et seq.**
Anticompetitive actions taken by hospitals, generally, **§ 18:2**
Antitrust principles, application of, **§ 18:5**
Application of antitrust principles, **§ 18:5**
Boycotting by hospital, **§ 18:3**
Case summaries, **§ 18:5**
Certificate of need (CON), hospital's opposition, **§ 18:3**
Community and payer moral suasion, **§ 18:3**
Competition between hospitals and. See entries throughout this topic
Conflicts of interest, **§ 18:2, § 18:3**
"Cost-shifting," **§ 18:2**
"Cross-subsidization," **§ 18:2**
Economic credentialing, **§ 18:3**
Economic interest. See entries throughout this topic
Employee non-compete agreements, ethical restraints, **§ 18:4**
Establishment of competing facility by hospital, **§ 18:3**
Ethical restraints, employee non-compete agreements, **§ 18:4**
Exclusive contracting policies, **§ 18:3**
"Free-riding," **§ 18:2**
Hospitals and, competition between. See entries throughout this topic
Investment interest. See entries throughout this topic
Issue background, **§ 18:2**
Joint ventures, **§ 18:3**
Lobbying by hospitals against, **§ 18:3**
Medical staff members, actions to combat competition from, **§ 18:3**
Medicare Prescription Drug, Improvement, and Modernization Act, **§ 18:2**
Noerr-Pennington doctrine, **§ 18:3**

PHYSICIAN-OWNED FACILITIES —Cont'd
Non-compete agreements of employee, ethical restraints, **§ 18:4**
Referrals, **§ 18:2**
Selective contracting policies, **§ 18:3**
Single-specialty hospitals (SSHs), **§ 18:2 et seq.**
Stark anti-referral laws, **§ 18:2**
Unfair competition, **§ 18:2**

PHYSICIANS
See also Practitioner Credentialing (this index)
Alaska House of Representatives, physician joint negotiation statute (Jan. 18, 2002), **App. D90**
Collective bargaining legislative exemption, letter from FTC to Insurance Committee, Ohio House of Representatives (October 16, 2002), **App. D93**
Exclusive contracts between hospitals and. Exclusive Contracts (this index)
Hospital acquisition of physician practices, **§ 15:32**
Joint negotiation statute
  Alaska House of Representatives, physician joint negotiation statute, **App. D90**
  Washington State House of Representatives, physician joint negotiation statute, **App. D91**
Joint ventures
  between hospitals and physicians, analysis, **§ 16:10**
  Provider-Controlled Contracting Networks (this index)
Mergers of practices of, **§ 15:32**
Network joint ventures. Provider-Controlled Contracting Networks (this index)
Washington State House of Representatives, physician joint negotiation statute (Feb. 8, 2002), **App. D91**

PLANNING
See also Health Planning; Health Planning Act; Health Plans (this index)
For mergers
See also Health Planning; Health Planning Act; Health Plans (this index)
hospitals, **§ 15:30**

PLASTIC SURGERY ASSOCIATES OF CONNECTICUT, LLC
Business review letter (June 28, 1996), **App. C68**

"POACHING"
Limitations on, ethical restraints, **§ 24:5**

PORTABLE AND MOBILE DENTISTRY
FTC Staff comments to Louisiana State Board of Dentistry regarding proposed modifications to Louisiana Rules regarding the practice of portable and mobile dentistry (Dec. 9, 2009), **App. D126**

PRACTICE FORM
Restraints on, ethical issue, **§ 24:7**

PRACTICE STANDARDS
Relating to quality, ethical issue, **§ 24:9**

PRACTITIONER CREDENTIALING
Generally, **§ 13:1**
Allied health practitioners, **§ 13:19**
Analysis under Section 1 of Sherman Act
generally, **§ 13:10**
capacity to conspire, **§ 13:11**
conspiracy in fact, **§ 13:12**
standard of analysis, **§ 13:13**
Analysis under Section 2 of Sherman Act, **§ 13:18**
Analysis under Section 1 of Sherman Act: analysis under rule of reason
generally, **§ 13:14**

PRACTITIONER CREDENTIALING—Cont'd
Analysis under Section 1 of Sherman Act: analysis under rule of reason—Cont'd
effect on competition, **§ 13:16**
intent and purpose, **§ 13:17**
relevant market, **§ 13:15**
Antitrust standing to challenge adverse decision, **§ 13:9**
Discovery in staff-privilege antitrust litigation, **§ 13:20**
Health Care Quality Improvement Act, **§ 9:12, § 13:8**
Hospital organization and the process of, **§ 13:2**
Legal theories and parties, **§ 13:3**
Minimizing antitrust risks, **§ 13:21**
Preliminary issues
generally, **§ 13:4**
Health Care Quality Improvement Act, **§ 13:8**
interstate commerce, **§ 13:5**
Local Government Antitrust Act, **§ 13:7**
state-action exemption, **§ 13:6**

PREDATORY CONDUCT
Section 2 of Sherman Act, diversification and
see also Anticompetitive Conduct (this index)
refusals to deal, **§ 17:9**
steering as predatory conduct, **§ 17:12**

PREDATORY PRICING
Under Section 2 of Sherman Act, **§ 6:6**

PREFERRED LABORATORY ACCESS NETWORK
Business review letter (Dec. 7, 1995), **App. C60**

PREFERRED PHYSICIANS MEDICAL GROUP
Business review letter (July 23, 1999), **App. C89**

PREFERRED PODIATRIC NETWORK INC.
Business review letter, **App. C45**

PRELIMINARY INJUNCTION
Pursuant to Section 13(b) of the Federal Trade Commission Act, **App. G10**

PREMERGER NOTIFICATION
''An Ounce of Antitrust Prevention is Worth a Pound of Consumer Welfare: The Importance of Competition Advocacy and Premerger Notification,'' before Eleventh Annual Competition Day, Santiago, Chile (Nov. 5, 2013), **App. E91**
Mergers and, **§ 15:8**
Requirements under Section 7 of Clayton Act, **§ 8:17**
Section 7A of Clayton Act, premerger notification form and instructions under amended, **App. B3**
Statement of Commissioner Christine S. Wilson in the matter of HSR Premerger Notification, **App. E144**

PRESCRIPTION DRUGS
FTC Staff Advocacy Letter to Centers for Medicare and Medicaid Services concerning any-willing-provider changes to Medicare prescription drug benefit program (Mar. 7, 2014), **App. D159**

PRESENTATION HEALTH SYSTEM
Advisory opinion, **App. D40**

PRICE DISCRIMINATION
Generally, **§ 7:1**
As vertical agreement under Section 1 of Sherman Act, **§ 5:9**

PRICE EXCHANGES
Price-Fixing Agreements (this index)

PRICE-FIXING AGREEMENTS AND PRICE AND WAGE EXCHANGES
Generally, **§ 19:1 et seq.**

PRICE-FIXING AGREEMENTS AND PRICE AND WAGE EXCHANGES—Cont'd
Ancillary price-fixing agreements, **§ 20:8**
Contracting networks. Provider-Controlled Contracting Networks (this index)
Ethical restraints on, **§ 24:3**
Exchanging or disseminating pricing information, competitor agreements to, **§ 19:6**
Exclusive contracts and vertical, **§ 14:15**
Forms of provider price-fixing agreements, **§ 19:4**
Horizontal, under Section 1 of Sherman Act, **§ 4:2**
Joint ventures. Provider-Controlled Contracting Networks (this index)
''Naked'' price-fixing agreements, **§ 19:3**
Negotiations among providers with payers, concerted, **§ 19:5**
Networks. Provider-Controlled Contracting Networks (this index)
Physician network joint ventures (Statement 8). Provider-Controlled Contracting Networks (this index)
Price exchanges. See entries throughout this topic
Provider-Controlled Networks (this index)
Statement 8. Provider-Controlled Contracting Networks (this index)
Statement 9. Provider-Controlled Contracting Networks (this index)
Vertical Price-Fixing Agreements (this index)

PRICING
Monopoly, under Section 2 of Sherman Act, **§ 6:5**
Predatory, under Section 2 of Sherman Act, **§ 6:6**

PRIMARY AND EXCLUSIVE JURISDICTION
Generally, **§ 9:6**

PRIMARY AND SPECIALIST MEDICAL CENTER, LLC
Business review letter (July 2, 1996), **App. C70**

PRIVATE ACTIONS
Generally, **§ 11:1**
Damages as element of damage action, **§ 11:8**
Defenses
generally, **§ 11:9**
antitrust defenses in nonantitrust cases, **§ 11:12**
in pari delicto and related defenses, **§ 11:11**
statute of limitations, **§ 11:10**
Effect of government judgments and prior violations, **§ 11:14**
Elements of
generally, **§ 11:2**
antitrust injury, **§ 11:6**
business or property, **§ 11:4**
causation, **§ 10:4, § 11:5**
damages, **§ 11:8**
injury, **§ 11:3**
standing, **§ 11:7**
Injunctive relief, **§ 11:15**
Parties liable, **§ 11:13**
Practitioner credentialing, antitrust standing to challenge, **§ 13:9**

PRIVATE HEALTHCARE SYSTEM
Advisory opinion, **App. D16**

PRIVATE TREBLE-DAMAGE LITIGATION
Injury in, under Robinson-Patman Act, **§ 7:11**

PRODUCTS
Separate and distinct, exclusive contracts and, **§ 14:4**
Tying Arrangements (this index)

PROKLAHOMA CARE, INC.
Business review letter (Jan. 17, 1996), **App. C61**

PROPERTY
As element of damage action, **§ 11:4**

PROVIDER-CONTROLLED CONTRACTING NETWORKS
Generally, **§ 20:1 et seq.**
Accountable care organizations, Federal Trade Commission and Department of Justice Statement of Antitrust Enforcement Policy, **§ 20:15**
Ancillary price-fixing agreements and clinical integration, **§ 20:8**
Clinical integration, ancillary price-fixing agreements and, **§ 20:8**
Exclusivity in physician network joint ventures and safety zones, Statement 8, **§ 20:6**
Federal Trade Commission and Department of Justice Statement of Antitrust Enforcement Policy, **§ 20:15**
Joint ventures. Physician network joint ventures (Statement 8), below
Market power
multi-provider networks, **§ 20:12**
physician network joint ventures (Statement 8), **§ 20:9**
Medicare Shared Savings Program, Accountable care organizations, **§ 20:15**
Messenger arrangements, **§ 20:14**
Multi-provider networks (Statement 9)
generally, **§ 20:10 to 20:13**
market power, **§ 20:12**
price-fixing agreements, generally, **§ 20:11**
vertical agreements, **§ 20:13**
Participation percentages, exclusivity, and safety zones, Statement 8, **§ 20:6**
Physician network joint ventures (Statement 8)
generally, **§ 20:4 to 20:9**
ancillary price-fixing agreements and clinical integration, **§ 20:8**

PROVIDER-CONTROLLED CONTRACTING NETWORKS —Cont'd
Physician network joint ventures (Statement 8)—Cont'd
antitrust safety zones, **§ 20:5, § 20:6**
exclusivity in physician network joint ventures and safety zones, **§ 20:6**
financial risk sharing and antitrust safety zones, **§ 20:5**
market power, **§ 20:9**
outside antitrust safety zones, **§ 20:7, § 20:8**
participation percentages, exclusivity, and safety zones, **§ 20:6**
Price-fixing agreements, generally, **§ 20:3 et seq.**
Vertical agreements, multi-provider networks, **§ 20:13**

PROVIDER DIVERSIFICATION
Generally, **§ 17:1**
And Section 7 of Clayton Act, **§ 17:7**
And Section 1 of Sherman Act, **§ 17:3**
And Section 2 of Sherman Act
generally, **§ 17:8**
steering as predatory conduct, **§ 17:12**
And Section 2 of Sherman Act: monopolization and attempted monopolization
generally, **§ 17:8**
diversification and leveraging, **§ 17:11**
diversification and predatory refusals to deal, **§ 17:9**
diversification and the essential facilities doctrine, **§ 17:10**
And steering by other providers, **§ 17:14**
Diversification and reciprocal dealing, **§ 17:6**
Diversification resulting from an exclusive dealing agreement, **§ 17:4**
Diversification resulting in a tying arrangement, **§ 17:5**

PROVIDER DIVERSIFICATION —Cont'd
Relevant legal theories, **§ 17:2**
Risk minimization in hospital diversification, **§ 17:13**

PUERTO RICO
Optometry, FTC and DOJ joint comments to Puerto Rico House of Representatives (May 18, 2016), **App. D182**
Treasury and Financial Affairs Committee, FTC Staff letter objecting to bill permitting health-care providers to collectively negotiate fees (Jan. 30, 2008), **App. D118**

PURCHASERS
Group purchasing programs, joint ventures and, **§ 16:8**
Mergers (this index)

PURPOSE OR INTENT
Practitioner credentialing and, under Section 1 of Sherman Act
generally, **§ 13:17**
see also Anticompetitive Purpose or Intent Element (this index)

QUALITY
Standards of practice relating to, as ethical issue, **§ 24:9**

QUEST ANALYTICS GROUP
FTC Staff Advisory Opinion concerning Non-Profit Institutions Act (Mar. 7, 2014), **App. D160**

"QUICK LOOK" RULE
Sherman Act Section 1 violations, anticompetitive effect elements, **§ 3:13**

RAMIREZ, EDITH
"Retrospectives at the FTC: Promoting an Antitrust Agenda," text of remarks before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E99**

REBECCA KELLY SLAUGHTER DISSENTING STATEMENT
Gateway Pet Memorial Services/West Coast, **App. F10**

RE BYSTOLIC ANTITRUST LITIGATION
FTC amicus brief, **App. D206**

RECIPROCAL DEALING
Diversification and, **§ 17:6**

RECIPROCAL DEALING AGREEMENTS
As vertical agreements under Section 1 of Sherman Act, **§ 5:8**

REFERENCE MATERIALS ON ANTITRUST GUIDELINES, POLICY, AND REGULATORY ENFORCEMENT IN HEALTHCARE AND GENERAL COMPETITION
Generally, **App. G**

REFERRALS
Physician-owned facilities, **§ 18:2**

REFUSAL TO DEAL
As anticompetitive conduct under Section 2 of Sherman Act, **§ 6:7**
Concerted, under Section 1 of Sherman Act, **§ 4:7**
Diversification and predatory, **§ 17:9**

REGULATED INDUSTRIES
Federal Government (this index)

REIMBURSEMENT
Health plan market power, payer monopoly power and low reimbursement, **§ 21:5**

RELATING TO WISCONSIN RATE REVIEW PROGRAM
Business review letter, **App. C4**

RELEVANT MARKETS
Generally, **§ 2:1 to 2:6**
Conclusion, **§ 2:6**
Exclusive contracts and, **§ 14:11**
Interstate commerce requirement, **§ 2:2**

RELEVANT MARKETS—Cont'd
Mergers and
geographic markets, **§ 15:11**
product market, **§ 15:10**
Under Section 7 of Clayton Act, **§ 8:4**
Under Section 1 of Sherman Act
geographic market, **§ 2:5**
practitioner credentialing and, **§ 13:15**
product market, **§ 2:4**

RELIEF
In civil cases of Antitrust Division, **§ 10:5**
Injunctive, in damage actions, **§ 11:15**
Preliminary, mergers and, **§ 15:8**
Under Section 7 of Clayton Act
generally, **§ 8:18**
Antitrust Division and Federal Trade Commission, **§ 8:18**
private parties, **§ 8:19**

REMARKS OF BILL BAER
Integration, Consolidation, Competition in the Wake of the Affordable Care Act, text of remarks before the New Health Care Industry Conference (Nov. 15, 2015), **App. E114**

REMARKS OF DEBORAH L. FEINSTEIN
''Antitrust Enforcement in Health Care: Proscription, Not Prescription,'' text of remarks before the Fifth National Accountable Care Organization Summit (June 19, 2014), **App. E98**
''FTC v. Sysco: Old School Antitrust With Modern Economic Tools'' text of remarks before GCR Live (Sept. 18, 2015), **App. E112**
''The Forward-Looking Nature of Merger Analysis,'' text of remarks (Feb. 6, 2014), **App. E96**

REMARKS OF EDITH RAMIREZ
''Retrospectives at the FTC: Promoting an Antitrust Agenda,'' text of

REMARKS OF EDITH RAMIREZ —Cont'd
remarks before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E99**
''The Horizontal Merger Guidelines Five Years Later'' text of remarks before Georgetown University Law Center Ninth Annual Global Antitrust Enforcement Symposium (Sept. 29, 2015), **App. E113**

REMARKS OF JON LEIBOWITZ
''Exclusion Payments to Settle Pharmaceutical Patent Cases: They're B-a-c-k!,'' prepared remarks before second annual in-house counsel's forum on pharmaceutical antitrust (Apr. 24, 2006), **App. E36**
''Pay-for-Delay Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers' Wallets, and Help Pay for Health Care Reform (The § 35 Billion Solution)'' (June 23, 2009), **App. E52**

REMARKS OF JOSHUA D. WRIGHT
''Antitrust Analysis of Reverse Payments After Actavis: Three Questions and Proposed Answers,'' text of remarks before the ABA Master Course VII (Oct. 10, 2014), **App. E101**
''FTC v. Actavis and the Future of Reverse Payment Cases,'' before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E90**
''Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission,'' before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E88**
''The FTC's Role in Shaping Antitrust Doctrine: Recent Successes and Future Targets,'' before the 2013 Georgetown Global Antitrust Symposium Dinner, Washington, D.C. (Sept. 24, 2013), **App. E89**

REMARKS OF J. THOMAS ROSCH
''Clinical Integration in Antitrust: Prospects for the Future,'' prepared remarks before AHLA and ABA Antitrust and Health Law Section 2007 Antitrust in Health Care Seminar (Sept. 17, 2007), **App. E42**
''Enforcement Strategies in the Health Care Industry,'' prepared remarks before ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E48**
''Litigating Merger Challenges: Lessons Learned,'' prepared remarks before Bates White Fifth Annual Antitrust Conference (June 2, 2008), **App. E47**
Monopsony and the meaning of consumer welfare, a closer look at Weyerhaeuser (Dec. 7, 2006), **App. E38**
Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context (Nov. 19, 2009), **App. E54**

REMARKS OF JULIE BRILL
''A Common Goal: The U.S. Federal Trade Commission's Healthcare Enforcement Program and its Implications for ACOs,'' text of remarks by Julie Brill, Commissioner, FTC, before the Sixth Annual Accountable Care Organization Summit Preconference (June 17, 2015), **App. E110**
''What's Past is Prologue: FTC's Competition and Consumer Protection Priorities,'' text of

REMARKS OF JULIE BRILL —Cont'd
remarks by Julie Brill, Commissioner, FTC, before the ABA Fall Forum (Nov. 6, 2014), **App. E102**

REMARKS OF LINA M. KHAN
Study on Pharmacy Benefit Managers, **App. E139**

REMARKS OF MARK BOTTI
''Observations on and From the Antitrust Division's buyer-side cases: How can 'lower' prices violate the antitrust laws'' at Antitrust Law Spring Meeting (Apr. 19, 2007), **App. E40**

REMARKS OF MARTIN GAYNOR
''Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care,'' text of remarks before the 2014 American Antitrust Institute Annual Conference, **App. E100**

REMARKS OF MARY LOU STEPTOE
(Speech), **App. E4**

REMARKS OF MAUREEN K. OHLHAUSEN
''Brother, May I, The Challenge of Competitor Control over Market Entry'' remarks before George Mason School of Law Global Antitrust Economics Conference (May 29, 2015), **App. E109**
''When Regulation Protects Privilege Instead of People: Government Restraints of Trade-A Competition Enforcer's Perspective,'' text of remarks before The Antitrust Enforcement Symposium 2015 of Journal of Antitrust Enforcement (June 27, 2015), **App. E111**

REMARKS OF PAMELA JONES HARBOUR
''A 'Check-Up' of Selected Health Care Activity at FTC'' (Mar. 30, 2005), **App. E32**
''Clinical Integration: The Changing Climate and What It Means for Care Coordination'' (Apr. 27, 2009), **App. E51**

REMARKS OF REBECCA KELLY SLAUGHTER
Antitrust and Health Care Providers: Policies to Promote Competition and Protect Patients, **App. E126**
Keynote, FTC/DOJ Pharmaceutical Task Force Workshop, **App. E145**

REMARKS OF TERRELL MCSWEENEY
Federal Trade Commission, Commissioner, text of remarks (Apr 28, 2015), **App. E107**
''Reflections on an Active Year in Merger Enforcement,'' keynote remarks (Feb. 5, 2016), **App. E116**

REMARKS OF THOMAS B. LEARY
Generally, **App. E24**

REMARKS OF TIMOTHY J. MURIS
Generally, **App. E23, App. E25**

REMARKS OF WILLIAM BLUMENTHAL
''The Rhetoric of Gun Jumping,'' remarks before Association of Corporate Counsel Annual Antitrust Seminar of Greater New York Chapter (Nov. 10, 2005), **App. E34**

REMARKS OF WILLIAM J. BAER
''Origin of the Species: The 100 Year Evolution of the Clayton Act,'' text of remarks before ABA Clayton Act 100th Anniversary Symposium (Dec. 4, 2014), **App. E103**

RESALES OF PREFERENTIALLY PRICED COMMODITIES
Generally, **§ 23:1**
Non-Profit Institutions Act
generally, **§ 23:3**
see also entries throughout this topic
Practical considerations, **§ 23:6**
Ramifications of preferential pricing on nonprofit health care providers
Federal Trade Commission advisory opinions, **§ 23:5**
NPIA court decisions, **§ 23:4**
Robinson-Patman Act
generally, **§ 23:2**
see also entries throughout this topic

RESOURCES
Antitrust laws, **§ 1:10**

RESTRAINING ORDER
Temporary, pursuant to Section 13(b) of the Federal Trade Commission Act, **App. G10**

RESTRAINTS
Agreements (this index)
Ethical Restraints (this index)

RETAIL HEALTH CARE FACILITIES
Letter from FTC to Illinois State Representative concerning proposed regulation of retail health care facilities (May 29, 2008), **App. D121**

REVERSE PAYMENTS
''Antitrust Analysis of Reverse Payments After Actavis: Three Questions and Proposed Answers,'' text of remarks of Joshua D. Wright, Commissioner, FTC, before the ABA Master Course VII (Oct. 10, 2014), **App. E101**
''FTC v. Actavis and the Future of Reverse Payment Cases,'' remarks of Joshua D. Wright, Commissioner, FTC, before the

REVERSE PAYMENTS—Cont'd
Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E90**

REVISED JURISDICTIONAL THRESHOLDS
Section 7A, Hart Scott-Rodino premerger notification filings
Clayton Act, **App. B26**

RHODE ISLAND ATTORNEY GENERAL
FTC staff letter to Patrick C. Lynch, Attorney General of Rhode Island (Apr. 8, 2004), **App. D104**

RIO GRANDE EYE ASSOCIATES, P.A.
Business review letter, **App. C91**

RISK MINIMIZATION
Exclusive contracts and, **§ 14:16**
In hospital diversification, **§ 17:13**
Practitioner credentialing and, **§ 13:21**

RISK SHARING
Provider-controlled contracting networks, antitrust safety zones, **§ 20:5**

ROBINSON-PATMAN ACT
Generally, **§ 7:2**
Exemptions and applicability, **§ 7:10**
Injury in private treble-damage litigation, **§ 7:11**
Overview of, **§ 23:2**
Resales of Preferentially Priced Commodities (this index)
Section 2(a)
competitive effects, **§ 7:5**
defenses, **§ 7:6**
essential elements, **§ 7:3**
jurisdictional requirements, **§ 7:4**
Section 2(c), **§ 7:7**
Section 2(f), **§ 7:9**
Sections 2(d) and 2(e), **§ 7:8**
Text of, excerpts, **App. A3**

ROSS HOSPITAL (FEB. 11, 1997)
Business review letter, **App. C77**

RULE OF REASON
Practitioner credentialing, analysis under Sherman Antitrust Act Section 1
generally, **§ 13:14**
effect on competition, **§ 13:16**
intent and purpose, **§ 13:17**
relevant market, **§ 13:15**
Unreasonably anticompetitive effect element, Sherman Antitrust Act Section 1, **§ 3:11**

RURAL HEALTH CARE COOPERATIVES
Letter from FTC to Minnesota State Representative concerning joint negotiations (Mar 18, 2009), **App. D122**

RWHC NETWORK, INC.
Business review letter (Nov. 12, 1996), **App. C76**

SANOFI/ MAZE THERAPEUTICS
Chair Lina M. Khan joined by commissioner Rebecca Kelly Slaughter, statement of, **App. B24**

SANTA FE, NEW MEXICO MANAGED CARE ORGANIZATION, INC.
Business review letter
(Sept. 16, 1998), **App. C87**

SANTE FE, NEW MEXICO MANAGED CARE ORGANIZATION, INC.
Business review letter
(Feb. 12, 1997), **App. C78**

SCHMIDT, JEFFREY
Prepared slides of Jeffrey Schmidt, Director, Bureau of Competition, before ABA Section of Antitrust Law 2007 Fall Forum concerning ''Critical Loss Analysis: A Merger Lawyer's View'' (Nov. 16, 2007), **App. E44**

SECOND CIRCUIT ORDER
Pharma Bro Martin Shkrelis lifetime ban, upholding
federal trade commission, statement of, **App. B25**

SEESKIN, PAAS, BLACKBURN & CO.
Business review letter, **App. C43**

SELECTIVE CONTRACTING
Physician-owned facilities, **§ 18:3**

SENATOR BRAD HUTTO
S.45 / H.3580 & S.669 APRNs, **App. D209**

SENATOR WILLIAM J. SEITZ
FTC staff letter concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D120**

SERVICE FOR YOU
Business review letter, **App. C19**

SERVICES
Conditional sale of one service, on purchase of another service, exclusive contracts and, **§ 14:5**
Joint ventures among competitors to provide new, **§ 16:9**

SETTLEMENTS
Exclusion Payment Settlements (this index)

SEWARD, JAMES I.
FTC letter to New York Senator James I. Seward concerning pharmacy-benefit-manager regulation (Mar 31, 2009), **App. D123**

SHARED MONOPOLY
Generally, **§ 6:17**

SHERMAN ANTITRUST ACT (SHERMAN ACT)
Generally, **§ 3:1**
''Effect on commerce'' test, **§ 2:2**
Expectation of effect on commerce, **§ 2:2**
''In commerce'' test, **§ 2:2**
''Infected activities,'' **§ 2:2**

SHERMAN ANTITRUST ACT (SHERMAN ACT)—Cont'd
Relevant geographic market, **§ 2:1**
Section 2
generally, **§ 6:1**
conspiracy to monopolize, **§ 6:16**
exclusive contracts, **§ 14:13**
mergers and, **§ 15:3**
practitioner credentialing, **§ 13:18**
Section 2: attempted monopolization
generally, **§ 6:13**
dangerous probability of success, **§ 6:15**
specific intent and predatory conduct, **§ 6:14**
Section 2: diversification and
generally, **§ 17:8**
diversification and essential facilities doctrine, **§ 17:10**
diversification and leveraging, **§ 17:11**
diversification and predatory refusals to deal, **§ 17:9**
steering as predatory conduct, **§ 17:12**
Section 1: diversification under
generally, **§ 17:3**
diversification and reciprocal dealing, **§ 17:6**
diversification resulting from an exclusive dealing agreement, **§ 17:4**
diversification resulting in a tying arrangement, **§ 17:5**
Section 1: fundamental concepts, relevant market
generally, **§ 2:3**
relevant geographic market, **§ 2:5**
relevant product market, **§ 2:4**
Section 1: fundamental concepts of
generally, **§ 3:1**
elements of Section 1 violation. Violations of Section 1 of Sherman Act (this index)
interstate commerce requirement, **§ 2:2**
Section 1: horizontal agreements under
generally, **§ 4:1**

SHERMAN ANTITRUST ACT (SHERMAN ACT)—Cont'd
Section 1: horizontal agreements under—Cont'd
agreements to exchange or disseminate information, **§ 4:3**
bid-rigging agreements, **§ 4:5**
concerted refusals to deal, **§ 4:7**
covenants not to compete, **§ 4:6**
horizontal market-allocation agreements, **§ 4:4**
horizontal price-fixing agreements, **§ 4:2**
mergers and joint ventures, **§ 4:8**
standard-setting programs, **§ 4:10**
unfair competition and dirty tricks, **§ 4:9**
Section 1: mergers, **§ 15:3**
Section 2: monopolization
generally, **§ 6:2**
monopoly power, **§ 6:3**
Section 2: monopolization—anticompetitive conduct
generally, **§ 6:4**
denial of access to essential facility, **§ 6:8**
leveraging, **§ 6:9**
mergers, **§ 6:11**
monopoly pricing, **§ 6:5**
other predatory or unreasonably exclusionary conduct, **§ 6:12**
predatory pricing, **§ 6:6**
refusals to deal, **§ 6:7**
text of, excerpts, **App. A1**
vertical integration, **§ 6:10**
Section 1: practitioner credentialing—analysis under rule of reason
generally, **§ 13:14**
effect on competition, **§ 13:16**
intent and purpose, **§ 13:17**
relevant market, **§ 13:15**
Section 1: practitioner credentialing under
generally, **§ 13:10**
capacity to conspire, **§ 13:11**
conspiracy in fact, **§ 13:12**
standard of analysis, **§ 13:13**

SHERMAN ANTITRUST ACT (SHERMAN ACT)—Cont'd
Section 1: vertical agreements under
generally, **§ 5:1**
distributorship terminations, **§ 5:4**
dual distribution, **§ 5:5**
exclusive dealing agreements, **§ 5:7**
price discrimination and commercial bribery, **§ 5:9**
reciprocal dealing agreements, **§ 5:8**
tying agreements, **§ 5:6**
vertical market-allocation agreements, **§ 5:3**
vertical price-fixing agreements, **§ 5:2**
Subject matter jurisdiction, **§ 2:2**

SIERRA COMMCARE, INC.
Business review letter (Aug. 15, 1996), **App. C72**

SIMONS, JOSEPH J.
''A Health Care Check on COPAs; Assessing the Impact of Certificates of Public Advantage in Health Care Markets'' (June 18, 2019), **App. E127**
FDA / FTC Biosimilars Workshop (March 9, 2020), **App. E130**

SINGLE-SPECIALTY HOSPITALS (SSHS)
Physician-owned facilities, **§ 18:2 et seq.**

SLAUGHTER, REBECCA KELLY
Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E147**
''Antitrust and Health Care Providers: Policies to Promote Competition and Protect Patients,'' **App. E126**
Contact Lens Rule (June 22, 2020), **App. E133**
Keynote remarks, Pharmaceutical Task Force Workshop, **App. E145**

SMITH, TERENCE L., M.D.
Business review letter (Oct. 17, 1996), **App. C75**

SOLICITATION
Limitations on, ethical restraints, **§ 24:6**
Of government action, antitrust exemption, **§ 9:8**

SOUTH CAROLINA HOUSE OF REPRESENTATIVES
FTC advocacy letter concerning supervision of advanced practice nurses (Nov. 2, 2015), **App. D173**
Joint statement of FTC and Antitrust Division on Certificate-of-Need laws and proposed legislation (Jan. 16, 2016), **App. D174**

SOUTH CAROLINA STATE HEALTH PLANNING COMMITTEE
U.S. Department of Justice Antitrust Division letter concerning certificate-of-need regulation (Dec. 8, 2006), **App. C97**

SOUTHEAST MANAGED CARE, INC.
Advisory opinion, **App. D44**

SOUTHERN ARIZONA THERAPY NETWORK, INC.
Advisory opinions (Dec. 7, 1995), **App. D58**

SOUTHERN HEALTH CORPORATION (MARCH 5, 1996)
Business review letter, **App. C63**

SOUTHWESTERN MICHIGAN HEALTH SYSTEMS AGENCY
Business review letter, **App. C12**

SOUTHWEST FLORIDA ORAL SURGERY ASSOCIATES
Advisory opinions (Dec. 2, 1996), **App. D65**

SOUTHWEST ONCOLOGY GROUP
Business review letter (Nov. 2, 1995), **App. C57**

SOUTHWEST ORTHOPEDIC SPECIALISTS (JUNE 10, 1997)
Business review letter, **App. C81**

SPECIAL COMMITTEE ON AGING, U.S. SENATE
Barriers to Generic Entry, Prepared Statement of FTC Before (July 20, 2006), **App. E37**

SPECIALIZED SERVICES
Joint ventures among competitors to provide new, **§ 16:9**

SPEECHES
Generally, **App. E et seq.**
See also topics beginning ''Remarks''
Abandonment by Providence Health & Services of plan to acquire Spokane Cardiology and Health Clinics Northwest, **App. E64**
''A 'Check-Up' of Selected Health Care Activity at FTC'' (Mar. 30, 2005), **App. E32**
''Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry; Why Consumers and the Federal Government are Paying Too Much for Prescription Drugs,'' **App. E50**
''Antitrust, Accountable Care Organizations, and the Promise of Health Care Reform,'' Edith Ramirez, FTC Comm., **App. E62**
''Antitrust Analysis of Hospital Networks and Shared Services Arrangements,'' **App. E12**
''Antitrust Evaluation of Pay-for-Delay Settlements: A Persistent Quest for Balance,'' **App. E67**
''Antitrust in Healthcare: A Keynote Address,'' **App. E27**
''Antitrust Issues in Settlement of Pharmaceutical Patent Disputes'' (Part I - Nov. 3, 2000), **App. E18**

SPEECHES—Cont'd
''Antitrust Issues in Settlement of Pharmaceutical Patent Disputes'' (Part II - Nov. 3, 2000), **App. E19**
''A Stepwise Approach to Antitrust Review of Horizontal Agreements,'' **App. E15**
Barriers to Generic Entry, Prepared Statement of FTC Before Special Committee on Aging, U.S. Senate Concerning (July 20, 2006), **App. E37**
''Bending the Cost Curve: The View from the Federal Trade Commission,'' Julie Brill, FTC Comm., **App. E75**
Brill, Julie, prepared remarks before North Carolina Bar Assoc., **App. E69**
''Combination and Collaboration in Health Care Markets: Antitrust as a Constraint in a Time of Change,'' **App. E5**
''Comments on Nuts and Bolts of Civil Antitrust Investigation by DOJ Involving Healthcare Industry,'' **App. E13**
''Competition and Health Care: A Prescription for High-Quality, Affordable Care,'' **App. E70**
''Consummated Merger Challenges—The Past is Never Dead,'' **App. E72**
Credit Suisse 2018 Washington Perspectives Conference, remarks at, (Jan. 10, 2018), **App. E124**
''Current Issues in Health Care Antitrust: Boycotts, Mergers, and Provider Networks,'' **App. E8**
''Current Issues in Health Care Antitrust Enforcement at FTC,'' **App. E14**
''Diagnosing Physician-Hospital Organizations,'' **App. E28**
''Efficient Justifications for Hospital Mergers,'' **App. E6**
''Exclusion Payments to Settle Pharmaceutical Patent Cases:

SPEECHES—Cont'd
They're B-a-c-k!," **App. E36**
"Health Care Guidelines and Associations—How Associations Can Work with the Department of Justice," **App. E2**
"How Pay-for-Delay Settlements Make Consumers and the Federal Government Pay More for Much Needed Drugs," **App. E49**
"Importance of Competition and Antitrust Enforcement to Lower-Cost, Higher-Quality Health Care," **App. E53**
"Integrated Joint Ventures," **App. E9**
"Joint Ventures in Evolving Health Care Markets," **App. E1**
Keynote remarks of Commissioner Rebecca Kelly Slaughter, Pharmaceutical Task Force Workshop, **App. E145**
Leibowitz, Jon, prepared remarks regarding stereotypes before the AMA, **App. E58**
Medco Health Solutions, FTC statement concerning acquisition by Express Scripts, **App. E73**
"New Entry Into Hospital Competition" (May 24, 2005), **App. E33**
"Oversight of the Antitrust Enforcement Agencies," **App. E66**
"Patent Settlements, Patent Reform, and Mergers: Recent Developments in Pharmaceutical Antitrust," **App. E65**
"Preserving Our Hometown Independent Pharmacies Act of 2011," **App. E71**
Recent Developments in the FTC's Antitrust Program for Health Care Markets", **App. E7**
Remarks of Mary Lou Steptoe, **App. E4**
Remarks of Robert Pitofsky, Chairman, FTC, before Committee on Judiciary
(Feb. 27, 1996), **App. E11**
(Jul. 29, 1998), **App. E11**
Respecting proposed regulations implementing the Affordable Care Act, **App. E63**
"State Action Immunity for Health Care Collaboration after FTC v. Ticor," **App. E3**
Statement Of Commissioner Christine S. Wilson in the matter of HSR Premerger Notification, **App. E144**
"The One-Size-Fits-All Approach of the Affordable Care Act," **App. E68**
"The Rhetoric of Gun Jumping," remarks before Association of Corporate Counsel Annual Antitrust Seminar of Greater New York Chapter (Nov. 10, 2005), **App. E34**
"Twenty-Five Years of State Antitrust Enforcement Applied to Health Care," **App. E16**
"Use Your Time Wisely: Do's and Don'ts for Effective Advocacy Before the Federal Trade Commission," **App. E17**
Varney, Christine A., prepared remarks before ABA/AHLA Antitrust in Healthcare Conference, **App. E57**
"Vertical Restraints with Horizontal Consequences: Competitive Effects of 'Most Favored Customer' Clauses," **App. E10**

STAFF COMMENT
North Carolina Senate Bill 743
give state action defense to UNC healths collaborative activities, **App. D205**

STANDARD-SETTING PROGRAMS
Under Section 1 of Sherman Act, horizontal agreements, **§ 4:10**

STANDING
As element of damage action, **§ 11:7**

ST. ANTHONY MEDICAL CENTER
Business review letter, **App. C35**

STARK ANTI-REFERRAL LAWS
Physician-owned facilities, **§ 18:2**

STARK COUNTY HEALTH CARE COALITION
Business review letter, **App. C16**

STATE-ACTION DOCTRINE
''License to Compete: Occupational Licensing and the State Action Doctrine,'' prepared Statement of FTC before the United States Senate Committee on the Judiciary (Feb. 2, 2016), **App. E115**

STATE-ACTION EXEMPTION
From antitrust, **§ 9:7**
Mergers, economic effects, **§ 15:6**
Practitioner credentialing, **§ 13:6**

"STATE ACTION IMMUNITY FOR HEALTH CARE COLLABORATION AFTER FTC V. TICOR"
(Speech), **App. E3**

STATE-ACTION PROTECTION
Collaborative activity, FTC Staff Advocacy letter to West Virginia House of Delegates concerning state-action protection (Mar. 9, 2016), **App. D178**

STATE ATTORNEYS GENERAL
Protocol for coordination in merger investigations between federal enforcement agencies and state attorneys general, **App. B3G**

STATEMENT
Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro M. Bedoya In the Matter of Welsh, Carson Anderson & Stowe (January 17, 2025), **App. G31**

STATEMENT 8
Provider-Controlled Networks (this index)

STATEMENT 9
Provider-Controlled Networks (this index)

STATEMENT OF COMMISSIONER
Christine S. Wilson, HSR Premerger Notification, **App. E144**
FTC and State of Rhode Island v. lifespan Corporation and Care New England Health System, **App. E138**
Rebecca Kelly Slaughter, Contact Lens Rule, **App. E133**
Rohit Chopra, Review of the FTCs Pharmaceutical Merger Enforcement Program, **App. E134**

STATEMENT OF INTEREST
United States of America in the case of Duffy v. Yardi Systems, Inc. (3-1-24), **App. G35**

STATEMENT REGARDING PHYSICIAN AGREEMENTS TO CONTROL MEDICAL PREPAYMENT PLANS
Advisory opinion, **App. D1**

STATE UNIVERSITY OF NEW YORK
Certificate of public advantage application, FTC staff submission, **App. D201**

STATUTE OF LIMITATIONS
As damage action defense, **§ 11:10**

STATUTES
Generally, **App. A et seq.**
See also specific entries throughout this index
Antitrust Laws (this index)

STEERING
Diversification and
by other providers, **§ 17:14**
under Section 2 of Sherman Act, **§ 17:12**

ST. JOHN'S HEALTH SYSTEM
FTC staff advisory opinion to (Sept. 13, 2006), **App. D112**

ST. LOUIS AREA BUSINESS HEALTH COALITION
Business review letter, **App. C25**

SUBCOMMITTEE ON FEDERAL FINANCIAL MANAGEMENT, GOVERNMENT INFORMATION, AND INTERNATIONAL SECURITY
''New Entry Into Hospital Competition'' (May 24, 2005), **App. E33**

SUBJECT MATTER JURISDICTION
Interstate commerce, **§ 2:2**

SUBURBAN HEALTH ORGANIZATION, INC.
FTC staff advisory opinion to (March 28, 2006), **App. D110**

SUMMARY JUDGMENTS
Generally, **§ 12:1**
Dismissal, generally, **§ 12:1 to 12:3**
Failure to state a claim, motions to dismiss, **§ 12:2**
Motions, generally, **§ 12:3**
Motions to dismiss, **§ 12:1 to 12:3**

SUMMARY REPORT
FDA/FTC workshop on a competitive marketplace for biosimilars, **App. D203**

SUPERVISION
Georgia Board of Dentistry, FTC comments concerning proposed amendments to rules governing supervision of hygienists, **App. D131**
Georgia State Senate, FTC Advocacy letter to Hon. Valencia Seay concerning supervision of dental hygienists (Jan. 29, 2016), **App. D175**
Massachusetts House of Representatives, FTC letter concerning removal of supervision requirement from nurse practitioners and nurse anesthesiologists (Jan. 17, 2014), **App. D157**
South Carolina House of Representatives, FTC advocacy letter concerning supervision of advanced practice nurses (Nov. 2, 2015), **App. D173**

SUPREME COURT DECISIONS
Federal Trade Commission (FTC), pharmaceutical patent settlements and Supreme Court, **App. E77**
''Lessons from the Commission's Supreme Court Trifecta,'' text of remarks of Jonathan Neuchterlein at American University Administrative Law Review Annual Symposium (Mar 20, 2015), **App. E105**
''Reflections on Supreme Court's North Carolina Dental Decision and the FTC's Campaign to Rein in State Action Immunity,'' Maureen K. Ohlhausen, FTC Commissioner (Mar 31, 2015), **App. E106**

TARRANT COUNTY MEDICAL SOCIETY
Advisory opinion
July 11, 1984, **App. D13**
May 25, 1984, **App. D12**

TELECOMMUNICATIONS
Delaware Board of Speech/Language Pathologists, Audiologists, and Hearing Aid Dispensers, amendment to telecommunication and telehealth regulations, FTC advocacy letter (Nov. 29, 2016), **App. D186**

TELEHEALTH SERVICES
Antitrust Division advocacy letter to Sen. Peter MacGregor, Michigan State Senate, concerning legislation addressing telehealth services (Nov. 29, 2016), **App. C103**
Delaware Board of Speech/Language Pathologists, Audiologists, and Hearing Aid Dispensers, amendment to telecommunication and telehealth regulations, FTC advocacy letter (Nov. 29, 2016), **App. D186**
FTC Advocacy letter to Alaska State Legislature concerning bill

TELEHEALTH SERVICES—Cont'd
permitting (Mar. 25, 2016), **App. D179**

TEMPORARY RESTRAINING ORDER
Pursuant to Section 13(b) of the Federal Trade Commission Act, **App. G10**

TENNESSEE
Letter concerning Ballad Health COPA expiration and certificate-of-need requirements for acute-care hospitals, **App. F21**

TENNESSEE DEPARTMENT OF HEALTH
FTC Staff advocacy letter to Malaka Watson, Tennessee Department of Health, concerning cooperative agreements and certificates of public advantage (Sept. 24, 2015), **App. D171**

TERMINATIONS
Distributorship, under Section 1 of Sherman Act, vertical agreements, **§ 5:4**

TESTIMONY
Division Director, Licensing & Certification at State of Maine
William Montejo, **App. G11**
Supporting LD 97
Division Director, Licensing & Certification at State of Maine, **App. G11**

TESTIMONY OF MARK BOTTI
''Competition in healthcare and certificate of need'' before Georgia General Assembly (Feb. 23, 2007), **App. E39**

TEXAS HOUSE OF REPRESENTATIVES
Advisory opinions, Joint Negotiations by Physicians (May 13, 1999), **App. D83**

TEXAS STATE BOARD EXAMINERS
FTC Staff advocacy letter to Simone Salloum concerning proposed

TEXAS STATE BOARD EXAMINERS—Cont'd
rules (Oct. 14, 2014), **App. D161**

TRADE REGULATION AND CONSUMER LAW
''Health Care Technology: Promoting Competition and Protecting Innovation,'' Maureen K. Ohlhausen, Commissioner of FTC, before Connecticut Bar Association Antitrust amp: Trade Regulation and Consumer Law Sections (Feb. 26, 2014), **App. E94**

TRANSPLANT ASSOCIATES
Business review letter, **App. C29**

TRISTATE HEALTH PARTNERS
FTC staff opinion letter not to recommend challenge of TriState's proposed program (Apr. 13, 2009), **App. D124**

"TWENTY-FIVE YEARS OF STATE ANTITRUST ENFORCEMENT APPLIED TO HEALTH CARE"
(Speech), **App. E16**

2006 MILTON HANDLER ANNUAL ANTITRUST REVIEW
Monopsony and the meaning of consumer welfare, a closer look at Weyerhaeuser (Dec. 7, 2006), **App. E38**

2007 ANTITRUST LAW FALL FORUM
Prepared slides of Jeffrey Schmidt, Director, Bureau of Competition, before ABA Section concerning ''Critical Loss Analysis: A Merger Lawyer's View'' (Nov. 16, 2007), **App. E44**

TYING ARRANGEMENTS
As vertical agreements under Section 1 of Sherman Act, **§ 5:6**
Diversification resulting in, **§ 17:5**

TYING ARRANGEMENTS—Cont'd
Hospital-physician exclusive contracts as
generally, **§ 14:3**
conditional sale of one service on purchase of another, **§ 14:5**
economic interest in sale of tied product, **§ 14:8**
effect on substantial amount of interstate commerce, **§ 14:7**
legitimate business justification, **§ 14:9**
market power in the market for the tying product, **§ 14:6**
separate and distinct products, **§ 14:4**

UNC HEALTHS COLLABORATIVE ACTIVITIES
North Carolina Senate Bill 743
give state action defense to UNC healths collaborative activities, **App. D205**

UNFAIR COMPETITION
Generally, **§ 7:1**
Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E147**
Physician-owned facilities, **§ 18:2**
Statement of enforcement principles regarding ''Unfair Methods of Competition'' under Section 5 of FTC Act (Aug. 13, 2015), **App. G2**
Under Section 1 of Sherman Act, horizontal agreements, **§ 4:9**

UNFAIR TRADE PRACTICES
Federal Trade Commission, ''Section 5: Principles of Navigation,'' Maureen K. Ohlhausen, Commissioner, before U.S. Chamber of Commerce, Washington, DC (July 25, 2013), **App. E86**

UNITED HEALTH GROUP
Antitrust Division background of closing investigation of acquisition of Oxford Health Plans (Jul. 20, 2004), **App. E31**

UNITED HEALTH GROUP—Cont'd

UNITED STATES SENATE COMMITTEE
Judiciary Subcommittee on Antitrust, Competition Policy and Consumer RightsOversight of the Enforcement of the Antitrust Laws, **App. E146**

UNIVERSITY OF MICHIGAN
Federal Trade Commission (FTC), staff advisory opinion to the University of Michigan concerning the Non-Profit Institutions Act, **App. D127**

UNREASONABLY ANTICOMPETITIVE EFFECT ELEMENT
Anticompetitive Effect Element (this index)

URONET OF LOUISIANA, LLC
Advisory opinions (Jan. 23, 1996), **App. D59**

U.S. DEPARTMENT OF JUSTICE ANTITRUST DIVISION
Justice Department (United States Department of Justice, Antitrust Division) (this index)

U.S DRUG DISTRIBUTION SYSTEM
Statement of FTC Bureau of Competition Deputy Director Rahul Rao on Lawsuit Against PBMs and the Role of Drug Manufacturers in Distorting Competition in the U.S Drug Distribution System (September 20, 2024), **App. G26**

"USE YOUR TIME WISELY: DO'S AND DON'TS FOR EFFECTIVE ADVOCACY BEFORE THE FEDERAL TRADE COMMISSION,"
(Speech), **App. E17**

U.S. V. AZHAA
"When Does a Group Purchasing Organization Become an Illegal Monopsonist" prepared remarks before AHLA annual meeting (June 26, 2007), **App. E41**

UTAH SOCIETY OF ORAL AND MAXILLOFACIAL SURGEONS
Advisory opinion, **App. D14**

VALLEY BAPTIST MEDICAL CENTER
Advisory opinions (Sept. 19, 1996), **App. D68**

VALLEY GASTROENTEROLOGISTS
Business review letter (July 7, 1997), **App. C82**

VERMONT
U.S. Dept. of Justice statement on closing of Vermont home health investigation, **App. E35**

VERMONT PHYSICIANS CLINIC
Business review letter (July 30, 1997), **App. C83**

VERTICAL AGREEMENTS
Mergers, **§ 15:29**
Provider-controlled contracting networks, multi-provider networks, **§ 20:13**
Sherman Act. Vertical Agreements (Section 1 of Sherman Act) (this index)
Vertical Price-Fixing Agreements (this index)

VERTICAL AGREEMENTS (SECTION 1 OF SHERMAN ACT)
Generally, **§ 5:1**
Distributorship terminations, **§ 5:4**
Dual distribution, **§ 5:5**
Exclusive dealing agreements, **§ 5:7**
Price discrimination and commercial bribery, **§ 5:9**
Provider-controlled contracting networks, multi-provider networks, **§ 20:13**
Reciprocal dealing agreements, **§ 5:8**
Tying agreements, **§ 5:6**
Vertical market-allocation agreements, **§ 5:3**
Vertical price-fixing agreements, **§ 5:2**

VERTICAL INTEGRATION
As anticompetitive conduct under Section 2 of Sherman Act, **§ 6:10**

VERTICALLY INTEGRATED PHARMACY
Specialty Generic Drugs
Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers (January 14, 2025), **App. G30**

VERTICAL MERGERS
Generally, **§ 15:29**
Under Section 7 of Clayton Act, **§ 8:14**

VERTICAL PRICE-FIXING AGREEMENTS
Exclusive contracts and, **§ 14:15**
Under Section 1 of Sherman Act, **§ 5:2**

VERTICAL RESTRAINTS
Most favored customer clauses, speech entitled "Vertical Restraints with Horizontal Consequences: Competitive Effects of 'Most Favored Customer' Clauses," **App. E10**

VETERANS ADMINISTRATION
FTC advocacy letter, advanced practice registered nurses restrictions (July 25, 2016), **App. D183**

VIOLATIONS OF SECTION 1 OF SHERMAN ACT
Generally, **§ 3:2**